passion transformsif s thing employee share p assion year passion people power invention product breakthrough ve bring human health year extraordinary testament fact passion people johnson johnson family company dna compel work corporation devote improve health wellbee people world passion inspire value embody credo employees johnson johnson family company practice treasured handed generation credo underscore personal responsibility need wellbee people serve liberate passion deepen commitment deliver meaningful health innovation johnson johnson pride know daily work make difference world year come passion continue transform human health cover olga vasukova like colleague johnson johnson llc moscow support government initiative modernize health care personal action reinforce smile father face obvious joy daughter sasha heart time papa pay visit story chairman letter shareholder improve health wellbee people world vital important business world meaningful business reason attract exceptional people capable skilled possess genuine passion make difference people live world thank dedication people advance human comprehensive broadly base health health wellbee johnson johnson deliver solid financial result take aggressive step position care company johnson johnson corporation future growth privileged play role help millions william c weldon chairman board director chief executive officer people stay consider young hip replacement preserve thank passion hard work ingenuity bone return active live new medicine people introduce hundred significant new product tibotec therapeutic division ortho biotech products lp line extension enterprise advance offer hope treatmentexperience hiv patient discover invent johnson johnson scientists think run option develop rd organization small sample new product new neutrogena aveeno skin care product introduce feature patent breakthrough longlaste protection time focus grow broad base sun harmful uva ray new diagnostic test human health care lead significant acquisition veridex llc allow doctor know enterprise include pfizer consumer healthcare breast cancer surgery womans cancer spread solidify position world premier consumer health lymph nod new implant technology care company key acquisition medical technology depuy orthopaedics inc enable adult previously strengthen position world large net sale dilute earning share dividend pay share billion dollar dollar dollar chairman letter broadly base medical advance unprec opportunity device diagnostic edente pace mean company hold opportunity scientific scientific innovation position innovationinclude major franchise include innovation innovation technology pharmaceutical convergencehas strengthen virology technology promise especially business launch broadly base company prezista darunavir convergenceha capacity adopt patient diagnose commercialize new promising treatmentresistant hiv technology quickly continue build pipeline course systemic especially broadly product target increase demand create world difficulttotreat countervail social force base company disease sign include pressure health important licensing agreement capacity adopt care budget political pressure position growth access affordability therapeutic areassuch commercialize new health care service oncology diabetes product demand lowcost hepatitis cwhere technology quickly alternative increase unmet need exist competition challenge science rapidly evolve intellectual property thank dedication force impact virtually people advance human health wellbeing participant health care marketplace johnson johnson deliver solid financial result approach address underlying challenge take aggressive step position corporation find right path stakeholder sustainable future growth worldwide sale grow record longterm growth johnson johnson year billion growth rate percent operational credo focus people responsibility wide growth percent range stakeholder customer patient family member net earning adjust billion grow employee communitie shareholder long percent outpace sale growth achieve acquainted need find winwin proposition solid earning growth year slow sale growth stakeholder world understand continue focus productivity cost management solid financial return come adjust earning share grow percent high rate earning completion billion win formula growth johnson johnson unique share repurchase program announce march company world change constant johnson johnson endure company strong growth opportunity uniqueness go exceptional exciting time world comprehensive longterm financial result deliver broadly base health care company product service decade derive management philosophy bring high value increase demand define unique business model guide progress science open new horizon improve extraordinary change science economics human human health wellbee health past century demographic geographic trend drive found share value embody credo strong demand category health care product broadly base human health care year ahead develop world population decentralize way operate business age expectation maintain active manage long term life furthermore rapid growth demand health follow time strategic principle product service develop nation create global source endure strength ability adapt expansion opportunity especially company like flourish dynamic everevolving industry encourage capacity execute market successful operation business near product sell country make ideally long term suit capitalize trend chart show exceptionally equally important science health wellbee consistent sale growth attain long term evolve rapidly thank wealth information log th consecutive year sale increase flow sequence human genome rd consecutive year earning increase adjust scientific breakthrough outside biologyin material special charge th consecutive year dividend science electronic computer science technology increase record match underpin sciencebased health care solutionsare company history johnson johnson annual reportfinancial highlight johnson johnson subsidiarie sale dollar billion change change sale customer million net earning million percent return average shareholder equity dilute net earning share cash dividend pay share market price yearend close believe strategic principle responsibility stockholder conclude serve past relevant future say operate business accord growth prospect look ahead strength responsibility embody credo stockholder require environment characterize historic realize fair return level rise demand increase economic credo connective tissue allow manage political complexity broadly base highly decentralize company long term credo foundation credo strategic foundation foundation strategic principle distinct advantage principle deeply hold common set value embody yearold document call credo cover strength breadth begin robert wood johnson ii write credo diversify hospital product johnson johnson johnson johnson publicly trade company fully commit broadly base human time guide action johnson johnson health care today leadership presence people level part world distinct segment health care industry consumer health simply credo challenge employee care medical device diagnostic pharmaceutical need wellbee people serve ask broadly base diverse segment health care supervisor colleague treat fellow employee help sustain consistently superior performance respect dignity spotlight responsibility johnson johnson shareholders year community live work portion business experience strong growth world community say final require steppedup investment future chairman letter sale segment research expense shareholder return billion dollar medical device million dollar total diagnostic sp index sp pharmaceutical index sp health care equip index johnson johnson pharmaceutical consumer year compound annual growth rate growth downturn economic condition health tralize business grow business fast care segment offset growth segment competitor drive innovate bring great important breadth offer key value marketplace internal discovery applica advantage enable elevate performance tion new science technology inlicense acquisition closeness customersour strong believe decentralized approach run partnership scientist professional business yield well decisionsin long runfor patient field human health geography health professional customer identify rapidly capitalize attractive decisionmaker close customer business opportunity emerge human health well position understand need spot emerge opportunity breadth enable finally decentralize approach manage quickly deploy necessary resource develop business tremendous magnet talent give second breadth allow strategic transfer knowledge people room grow room explore new idea new technology talent capability internally develop skill career business platform business segment example strategic transfer knowledge business strength focus long term manage business platform business segment highlight marathon sprint source follow page story people endure financial strength innovative product introduce manage business long term keep focus breadth give clear advantage underlying performance business conscious converging technology increasingly breakthrough innova ongoing performance time frame focus keep tion new adjacent market enable careful business healthy long term integration multiple technology people accus force anticipate capitalize change tome work business segment look future business different incorporate technological breakthrough achieve impor lensesthrough eye new customer new market tant innovation customer like access new technology new fiscal reality desire capitalize knowhow proprietary information technology resource change global health care environment favor company corporation consumerdriven health care rationale finally breadth allow leverage scale acquire pfizer consumer healthcare increasingly competitive global environment manage business long term lead efficient application deployment resource intensify investment need maintain leadership globe ve able optimize cost infrastructure position key growth market particularly area manufacture finance longterm view enable prudent risk procurement information technology innovative idea completely new way thing new well product alternative therapeutic strength decentralize approach decentralize approach novel technology new well manufacturing manner operate business marry good process longterm investmentssuch quality small companiesan entrepreneurial drive investment veridexs fledgle cellular molecularlevel growth close proximity customerswith resource diagnostic platformhave power potentially transform knowhow investment capital fortune company practice medicine initial strategic approach give advantage investment ethicon endosurgery inc year ago centralize operation strong sense ownership lead revolution minimally invasive surgery entrepreneurship agility accountability seldom see manage long term enable smarter large multinational corporation leadership acquisition deliver longterm shareholder value employee operate company world willing important challenging work require intensely competitive look leader decen sustained effort order achieve significantand possibly johnson johnson annual reporttransformationaloutcome long view give courage walk away strategic principle negotiate table believe price tag acquisition deliver strong longterm return shareholder investment manage long term entail careful evaluation longterm broadly base prospect business regularly evaluate business human health product portfolio tough decision curtail project divest manage entire business decentralize finally manage long term approach share value systemha long term help earn reputation company worthy trust trust open door opportunity growth open door prospective business partner new product idea new technology found share value door research institution work health advance tomorrow open door policy maker advocacy group want hear perspective improve health care found share value foundation strategic principle system country story deeply hold common set value embody yearold document page call credo manage business long term allow focus shape future broadly base human health broadly base diverse simply react change segment health care help sustain consistent superior performance johnson johnson shareholders year important breadth offer key advantage enable consumer health care highlight elevate performance momentous year consumer health care business completion decentralize approach decentralize manner operate acquisition pfi zer consumer healthcare business marry good quality small company pch december solidifi ed position resources knowhow investment capital fortune company world premier consumer health care company extend leadership manage long term manage business long term consumer health category keep focused underlying performance business world diverse consumer health conscious ongoing performance time frame focus keep portfolio large sustainable platform business healthy long term growth approximately half pch sale outside acquisition expands reach health wellbee world attractive highgrowth market bring grow turn otc medicine nonprescription endure brand name complement portfolio solution meet health need high level dispos strong iconic brand broaden oral health care able income develop nation create increase business signifi not franchise billion demand consumer health product region sale transform overthecounter otc large population business nearly double size solidify position pch acquisition good worldwide leader nonprescription medicine year consumer health care business reach acquisition substantially diversifi es otc portfolio nearly billion sale total consumer health provide entry highpotential category business introduce new product smoking cessation signifi not line extension help drive total sale growth strategically acquisition vitally important percent year review consumer health care market consumer health care product page increasingly attractive demographic social believe pch acquisition access shift favor increase demand consumer health product scientifi c knowledge technology fl owe consumer take great interest responsibility pharmaceutical medical device diagnostic chairman letter business position continue world leader tablet jurnista prolongedrelease tablet hydromor scientifically base professionally endorse consumer phone hcl prezista darunavir ionsys fentanyl health care product iontophoretic transdermal system receive approval significant line extension key product major pharmaceutical highlight overall environment market include risperdal risperidone pharmaceutical industry continue challenge treatment irritability associate autism remicade world downward pressure price infliximab treatment chronic severe reimbursement continue patent multibilliondollar plaque psoriasis pediatric crohns disease addition productsinclude ownface expiration receive authorization european health come year good year authority restore subcutaneous administration pharmaceutical business action take early eprex epoetin alfaerypo epoetin alfa anemia patient chronic kidney disease mid communicate investment community plan file secure approval new prescription medicine end m pleased report remain track meet goal fortify pharmaceutical pipelinealready robust point historyby add new compound strategic licensing agreement include potential insulin sensitizer treatment diabete oncology compound novel protease inhibitor treatment hepatitis c reorganize pharmaceutical business create franchise focus disease central nervous system cns internal medicine m second focused biotech immunology oncology bio focus virology cnsim business responsible sustain leadership position cns pain management build new global growth platform antibacterial cardiovascular disease bio business responsible strengthen global leadership immunemediate inflammatory disorder anemia management expand emerge global growth platform oncology indicate previ ously virology business work build leadership position range virologic disease high unmet medical need medical device diagnostic highlight medical device diagnostic mdd segment perform solid organic growth couple strategic acquisition segment position future growth mdd share value help earn trust respect year review medical device diagnostic essential company devote improve page health wellbee people world total sale grow percent bring mdd business christine poon billion annual revenue continue vice chairman board director large globally diverse medical device diagnostic business world decade strengthen pipeline start pay innovation continues drive strong organic growth new drug approval strong nearterm pipeline mdd business percent mdd position mitigate impact patent sale come product introduce past year expiration remainder decade beginning acquire total sale growth pharmaceutical segment strategically important medical device company percent continue build future growth example focus complementary growth hand significant accomplishment business innovation llc leader plate technology wrist segment year review pharmaceutical hand fracture important addition fastgrowe page trauma business depuy orthopaedics inc franchise receive regulatory approval market acquisition animas corporation leader insulin new productsinvega paliperidone extend release delivery system enable lifescan inc world leader johnson johnson annual reportdiabete monitoring device commitment management enter diabetes treatment read story market important story key philosophy anchor acquisition initial business development step lifescan plan follow page trust value system embody develop integrate solution ll believe human total management health exceptional credo allow patient disease business type future medical system people attract deal complexity sa company develop businessand specifically manufacture markets johnson johnsonare balance shortterm arthroscopic system add drive ordinary strength depuy fast desire serve succeed longterm growth grow sport medicine business business emphasis remain highly minimally invasive procedure optimistic future acquisition vascular growth prospect control systems inc business improve human ethicon inc add momentum ethicon women health health wellbee base unprecedented demographic portfolio addition invasive treatment option geographic social trend uterine fibroid relate symptom broadly base comprehensive company acquisition add critical mass cardiovascular fieldone wellbalance portfolio business business ensure medical add complementary post consumer health care medical device diagnostic catheterization closure technology femoral artery pharmaceuticalswe harness benefit increase important bring critical mass cordis demand continue work closely corporation rd talent pool premier advanced stakeholder health care system research development facility interventional management philosophy anchor value system cardiology near san francisco conor medsystem embody credo allow deal complexity unique control drugdelivery technology balance shortterm longterm growth explore range therapeutic category base outlook growth health care immediately contribute development confidence strategic approachinclude unique generation technology aim advance standard benefit broadly base health care businesseswe care treatment cardiac vascular disease commit deliver capitalefficient profitable growth believe impressive number new product intro participate fastestgrowe segment human duction exciting product mdd pipeline health care acquisition bring building sustain leadership position base unique competitive advantageswill enable remain superior science innovation world leader medical technology accelerate growth manage business achieve superior rate exciting health care segment return shareholder thank conclude d like moment real strength corporation acknowledge retire board member exceptional people talent drive passion contribution company aspiration difference world trait wish recognize ann jordan retire enable bring forward innovation improve live board director april mrs jordan wellbee people world trait elect board year ago bring deep embody character quality peoplehave experience health care social service bear help help deliver superior performance shareholder guide company especially role chairman continue source endure success nomination corporate governance committee member future compensation benefit committee past chairman public policy advisory committee wish thank recently retire vice chairman board director chief financial officer william c weldon robert j darretta year commitment chairman board directors johnson johnson steady hand financial helm chief executive officer corporation past decade bob march instrumental help deliver consistent sustainable superior performance visible vocal exclude inprocess research development guidant acquisition agree proponent endure strategic principle ment termination fee reconciliation nongaap financial measure chairman letter story new product family company introducesbehind partnership advance health wellbee people world stand team people passion story story accomplishment reveal character people aim company read story hope ll strategic principle play realityhow liberate people pursue consumer research insight solve scientifi c puzzle pursue big bold vision collaborate colleague half world away real diff erence people live passion transform fun sun year bicoastal cooperation skin care scientist work diff erent johnson johnson company result remarkable sunprotection breakthrough patent advanced sunscreen system strong eff ective longerlasting protection dangerous kind damage sun ray infl ict human skin dermatologist call big link sun exposure conse sunprotection innovation year quent need protection manufacturer paradigmtransforme technology skin care product begin add new sun provide stable broad protection protection remarkably wide range dangerous uva ray penetrate deeply skin care product long spf skin layer reduce collagen elastin sun protection factorbecame price uva ray clinically implicate sun market entry add benefi induce age skin skin cancer new skin care product incidental exposure sun cumulative consumer get false sense explain curtis cole phd photobiologist security high spf number bicoastal teamwork senior director skin care technology sunscreen product contain curtis cole phd leave johnson johnson consumer product uva fi lter avobenzone avoben rick woodin company division johnson johnson collaborate year zonethe eff ective broadspectrum fi lter consumer company inc skillman nj block uva raysbreak apart molec time single tiny photon sunlight unprotected ular level absorb energy sunlight early skin tip point cancer lab team try photostabilize avobenzone add evidence uva damagewhich include wrinkle chemical year eff ort find sag mottlingmay reveal year chemical call dehn help stabilize avobenzone unprotected skin expose sun contrast percentand want high level stability uvb rayswhich attack skin uppermost layer cause sunburn matter minute solution arrives add ingredient oxybenzonewe see interesting chemical mechanism year research take year research action dehn accept excess energy absorb development work dr cole west coast partner avobenzone transfer oxybenzone convert rick woodin photochemist director product uv light harmless red light sacrifi ce development neutrogena corporationto crack uva avobenzone ability absorb incoming photon protection code help franchiselevel marketer seek year add cole develop portfolio skin care product unparalleled sun finally remarkably longlaste sunscreen protection neutrogena aveeno trademark break sunlight block recall dr cole mid american academy harmful ray fi nal touch add conven dermatology launch intensive publiceducation program tional uvb fi lter fortify spf provide people true skin cancer raise consciousness world broadspectrum protection johnson johnson annual reportsoare success neutrogena aveeno advance sunscreen product fly retail shelf light texture easily absorb provide maximum protection sun damaging ray dr curtis cole phd photobiologist senior director skin care technology johnson johnson consumer product company advise important people remember reapply sun protection swim parent remember reapply children skin break water explain woodin curt able write natural ingredient clinically prove johnson johnson patent new synergistic technology skin tone improve blotchiness discoloration afford intellectual property protection current cause previous sun exposure aveeno regulatory guideline enable rapid product deployment product contain patented total soy complex marketplace idea good execu natural moisturizer vitamin e strong antioxidant tionso work hard consumer delightful slow uvainduce free radical chain reac aesthetic experience possible new technology tion think cause wrinkle otherwiseyouthful skin aveeno call new patent technology active gotomarket strategy neutrogena photobarri complex aveeno successfully launch new line skin care product contain newly patent advanced sunscreen s curt work technology neutrogena roll new decade exciting new exponentially transforma consumer product special dermatologist tive project say woodin s people dispense call new technology helioplex scientiststo break barrier bring forward new invention aveeno launch new advanced sunscreen product advance boundary technology american optometric association recognize vistakon uvblocke lense cristina schnider director association aoa commission dr derrick artis director customer medical affairs vistakon division ophthalmic standard development play role johnson johnson vision care inc contact lens line offer uv securing aoa seal add please oversee effort se protection hope generate awareness cure acuvue advance provide similar absorption level explain potential lense help acuvue oasys brand contact dr schnider acuvue advance reduce cumulative lense firstever seal acceptance acuvue oasys brand contact lense effect uv radiation dr derrick artis ultraviolet absorb contact contact lense meet show increase chance dr cristina schnider lense american optometric high uvblocking standard develop eye problem later life fun sun passion transform social responsibility f olga vasukova personal responsibility feel employee johnson johnson llc moscow support government initiative modernize health care give happen father personal olga study eye harvard business school employee johnson johnson papa nikolay vasukov come family company serve russia russia visit night cis russian government dinner nikolay feel chest pain new initiative phoned ambulance challenge improve health recall vasukova friend love one strategic affair director surprisingly people undertake johnson johnson llc medical mission resultsdriven mix russia headquarter moscow professional commitment youthful take papa hospital vigor intense personal interest doctor say narrow blood say naira adamian country manager vessel restrict blood flow janssencilag russia coronary artery perform coronary artery catheter firstever award ization insert baremetal stent civic initiative artery open stent russia cis cordis corporation local johnson johnson company today nikolay vigorous support training program medical yearold visit vasukova professional underwrite yearold granddaughter sasha educational philanthropic daughter energy effort advance new health year ago interventional cardiologist burn papa keep right insert cordis baremetal stent care agenda say vasukova nikolay vasukovs coronary artery today russian enjoy visit daughter olga government recognize energetic granddaughter sasha not wonderful contribution present kremlin recently issue directive call johnson johnson inaugural annual corporate comprehensive upgrade russian health care system social responsibility award selection committee personal action not wonderful award lead representative sector russian grandfather kind medical care russian societypoliticians scientist artist papa receive ask vasukova award cite johnson johnson civic initiative russian government not agree speech include support kremlin directive russian president vladimir contribution victim putin declare want decisive prudent step terrorist attack school beslan chechnya take city town village modernize health support child cerebral palsy congenital heart care russia entire commonwealth disease leukemia blindness independent state cis support major hivaid philanthropic program good corporate citizenship russia johnson johnson family company support educational philanthropic effort advance nation new health care agenda russian government recognize contribution present company inaugural annual corporate social responsibility award johnson johnson annual reporttogetherness join hand run moscow red square johnson johnson llc employee leave right igor nemchenko manage director consumer group russia vladimir makatsaria managing director johnson johnson medical russiacis naira adamian country manager janssencilag russia sandy mcintire managing director consumer group ukraine cilag gmbh international responsibility take seriously respon furthermore consumer company brand sibilitie outline credo johnson johnson llc recognize prestigious effie gold large health care company effie trust brand award awareness russia say vladimir makatsaria managing director trust ve earn russian consumer say johnson johnson medical russiacis word igor nemchenko manage director consumer group russia business milestone positive effect strive bring science consumer health prod wholehearte effort support government seek uct s important contribution health provide affordable goodquality health care russian wellbee people serve russia adult child june johnson johnson llc open new squaremeter office heart moscow bring local active partner active partner employee roof time sight russian government support health care reform greet day credo etch large glass panel education say adamian health science policy national award corporate social respon maker seek counsel range good practice sibility previous year johnson johnson llc receive ve able draw knowledge colleague moscow employer year award human johnson johnson family company resource management respect russian business journal employee play positive role future explain makatsaria tantamount second national russian health care play role award percent company presence remarkable passion conviction russia headquarter moscow personal dimension social responsibility passion transform vision beautifully nce success new product exceed creator expectation case point new line acuvue brand contact lense design specifically enhance attractiveness dark asian eye fact new line disposable contact lense add literal layer mean say beauty eye beholder lens feature dark outer ring embed lens make wearer iris appear large extremely subtle effect female develop response asian customer research insight male asian contact lens wearer notably korea japan help day acuvue market leader find particularly desirable involved develop new brand late addition line day acuvue define pleased product exceed expectation vivid style cosmetic contact lense launch korea koreanborn employee johnson johnson vision care inc singapore china japan fall style karren koo confident outset offer dramatic option want vibrant irisenhancing concept strike responsive chord irisenhance effect contact lens wearers asia lens lens new day acuvue define tale karen kooat time late strong pipeline vision care product launch johnson johnson vision care inc marketing manager base past year seoul koreadetected consistent response market example acuvue advance brand focus group asian woman keep say want lens contact lense astigmatism debut eye appear big distinctive koo silicone hydrogel daily wear contact lens people astig recall keep come research time matisma vision condition common million child additional research show customer want teenager adult addition day acuvue moist brand effect beautiful subtle natural contact lenseswith breakthrough lacreon technology bear word lense need launch year europe middle east africa beauty secret koo add feel certain considerable success japan day acuvue moist respond favorably combine subtle beautydriven fastestgrowe product category iris enhancement outstanding health benefit new irisenhancing product day acuvue define popular day acuvue lense brand contact lensesincluding firstlaunche accent meeting meeting koo press newproduct style new vivid stylehas prove wildly idea colleague market rd gentle popular asiapacific region new brand persistence finally reward invite dr karin mccarthy leave karren koo partner karen half world away native johnson johnson annual reportat right dark outer ring embed lens day acuvue define make iris appear large denmark dr karin mccarthy manager cosmetic stay close voice customer product development cosmetictint platform research right clinical trial subtle refinement development center vistakon division dramatically enhance appeal johnson johnson vision care inc jacksonville fla day acuvue define launch korea koos wontbedenie competitive spirit find kin november japan big asian market dr mccarthy olympian represent denmark february year new lense swimming event say dr mccarthy mutual friend roll china singapore taiwan hong kong thailand company agree karren market malaysia response extremely positive research partner perfect professional tag team able female consumer age innovation hand marketbase sciencebase attract new people contact lens category say koo issue arise develop exciting new beautyenhance product line socalle asian eye strong vision vision business year mark th anniversary johnson johnson vision turn point japan critical turn development care business whichmuch like beauty contact lense product clinical trial japan asian womenwas create paradigmshifting approach essentially virgin market irisenhance lense base directly consumer insight acuvue worlds course study dr mccarthy ensure cosmetic effect disposable contact lens prototypical day acuvue define lens overall perspective vision care business aim appeal japanese consumer equally important provide healthy vision gathering input eye care professional ensure lens day global market leader disposable contact design meet need lens market turn koo learn japanese consumer prefer blaze new trail global marketplace subtle possible appearance iris enlargementthe equiva contact lense put great emphasis satisfy lend extrathin eyeliner eye makeup product special need desire customer different geogra feedback japanese consumer give karin phie culture say koo day acuvue define nuance mull recall koo know perfect example vision beautifully passion transform power knowing breast cancer surgeon face frustrating midoperative moment close womans surgical wound know breast cancer cell metastasize spread patient lymph node answer come rightbut phd scientist lead early day later biopsy report development genesearch available news platform vice president bad doctor patient europe middle east africa emea wound heal ask orthoclinical diagnostic inc come moremore orthoclinical new diagnostic preop counsel signoff platform genetic detective anesthesia surgery hunter rogue dna look recovery pain scar molecular level dna anxiety present dna indicate fortunately alltoofamiliar spread cancer scenario need occur detect rogue dna lymph nod essential staging treat wait new disease precision add atkin dnabase diagnostic tool finding think genesearch breast lymph node nearly impossible limitation bln assay deliver test result underlie technology minute breast team work project think cancer patient operate outside box develop novel table false start heal approach detect rogue dna wait day news genesearch brand veridex intraoperatively good bad secondsurgery develop product base molecular heartache technology gene expression profile vanguard new era gene array help physician genesearch assay use today medical detect presence cancer early molecularlevel patent technology decision base vitro diag diagnose stage andor accurately characterize disease nostic testing conduct test tube control far quickly environmenta field orthoclinical worldwide genesearch quickly obtain result leader say roy davis orthoclinical company group status sentinal lymph node say dr jeanmarie chairman focus shift lab operation patient nogaret chief breast surgeon institut julesbordet brussels outcomes diagnostic tool like genesearchand belgium benefit patient medical veridex platform cellsearchwill help write big team economical chapter history medicine represent vanguard new era cellular molecularbased diagnostic pioneer diagnostic new genesearch diagnostic enable doctor manage patient wellness test pioneer veridex llc genesearch bln cope illness test enter european market mid compliance orthoclinical forefront major transformation eu vitro medical device regulation receive happen diagnostic company approach favorable fda advisory panel review december pronged veridex introduce new diagnostic platform early doctor detect metastasized breast cancer oncology orthoclinical franchise development group woman lymphatic tissue well outcomeand actively engage identify new biological marker s genesearch come explain david atkin select category major unmet medical need johnson johnson annual reportnovel diagnostic work identify novel diagnostic prognostic marker say yixin wang leave phd executive director research development veridex genetic detective look dna present dna indicate spread cancer explain david atkin right phd vice president emea orthoclinical diagnostics inc lead early development genesearch marker validate foundation new veridex molecular testing pipeline highvalue diagnostic teststest potential wang orthoclinical responsibility support identify disease state early stage pharmaceutical research development team biomarker cellsearchunveiled identifie enumerate evaluation drug development characterize circulate tumor cell directly game detect cancer cell wholeblood sample currently available use early possible point say wang s metastatic breast cancer clinical trial progress genesearch cellsearch platform application additional cancer design look forward bring series genesearch cellsearch test market come work project leader collective longterm dream orthoclinical atkin genesearch yixin wang phd executive veridex say davis world cancer rarely director research development veridex say wang fatal diabete fullblown researcher la jolla work expand heart attack circumvent early detection genesearch cellsearch facilitate early detection european introduction genesearch bln cancer work identify novel diagnostic test testament way make prognostic marker major type cancer support dream reality power know passion transform human vs microbe hroughout history humanitys bad enemy infectious disease cause microbesonecelle small multicelle life form infectious disease cause bacteria viruse important cause mortality century continue medical challenge say paul stoffels md company group chairman research development cns central nervous system internal medicine founder tibotecvirco company acquire specialize new treatment viral infection widely spread epidemic call pandemic deadly hiv infect estimate million people kill million imaging aid globally technology tuberculosis million portray humanitys lead cause people bad enemy death infect case hiv infectious disease hepatitis c astound worldwide virus hcv detail year milestone sciences battle global infectious disease great unmet hiv year case aids medical challenge generation say julie mchugh unnamed report center disease control company group chairman virology infectious disease like say stoffel dedicate career battle hiv hcv tb truly global health issue require world lethal virus year pharmaceutical industry create innovative solution clinical trial antiretroviral drug inhibit develop new bestinclass compound hiv genetic material patient blood bring medication patient need year debut protease inhibitor industrialize develop country prevent virus create billion innovative science address urgent need believe new copy daily hivpositive patient opportunity build new sustainable business real impact epidemic worldwide new protease inhibitor year johnson johnson operate company launchedin record unique rd process prezista result unique timea new protease inhibitor pi patient pharmaceutical research development process rely fail previous therapy pi new drug hiv drugresistance insight glean diagnostic tool prezista darunavir know tmc market pioneer virco affiliate tibotec virco perform tibotec therapeutic division ortho biotech diagnostic test chart molecular level product lp country tibotec division type resistant hiv virus worldwide tibotec janssencilag company signal start information design molecule able new global virology business franchise johnson johnson inhibit replication prevalent drugresistant franchise pipeline robust novel investi strain virus gational medication hiv hepatitis c hcv resistance truly benefit patient tuberculosis tb tb important opportu concern efficacy safety tolerability conve nistic infection hiv patient world nience prezista important new option treatment johnson johnson annual reportwhere begin paul stoffels md right company group chairman research development reunite mechelen belgium found member aidsfighte research team clockwise hilde azijn senior scientist tibotec clinical virology kurt hertog vice president tibotecvirco scientific operation mariepierre de bethune vice president tibotec clinical virology experience adult patient fail stoffel recall late socalle cocktail resistant protease inhibitor allow drug therapy turn aids manageable patient live low level virus year chronic disease like diabete hide reality attain undetectable viral load goal consistent virus continue build resistance threaten current treatment guideline say roger pomerantz md destroy hope people work hard facp president tibotec research development live productive life patient hearing respect development prezista teach hiv infection drugresistantand viral great deal treat global infectious disease load increase decreasingis secondworst day general continue pomerantz show longterm life exceed day physician give suppression virus microbe require development original diagnosis compound fit virus neatlyand likewise fit felt extra mile patient patient need additional study ongoing evaluate matter long arduous task aheadso longterm outcome prezista therapy head heart hand work exceptional commitment entire organization tibotec virco science hero yearlong behindthescene record time able discover develop novel story tibotec create prezista illustrate nimble drug build new organization people creative science able find way increase core success entire team commit make genetic barrier resistance insidious smart virus difference patient live hivaid globally prove master disguise mutation tibotecvirco vice president scientific operation opportunistic survival kurt hertog stoffel begin human vs microbes discipline pay year elapse study human january submission filing december say stoffel drugdevelopment term extremely short time deep commitment hiv addition prezista know tmc development process tibotec novel antiretroviralstmc tmcin development investigational drug nnrtis nonnucleoside reverse transcriptase inhibitor tmc latestage develop ment investigational nnrti significant activity patient prior nnrti failure clinical trial conduct investigate use combination prezista tmc early development compound highly potent successful backbone fixeddose combination therapy single pill company continue create path world hiv nnrti compound tmc license company international partnership microbicide nonprofit product development partnership develop ment vaginal microbicide agreement sign global health infectious disease represent great unmet royaltyfree licensing arrangement medical challenge say julie mchugh company group chairman kind microbicide research virology add roger pomerantz md facp president tibotec research approach development new compound prezista fit hiv neatly repeat manufacturer make extremely difficult virus mutate say team engineer failure create hiv woman special study research timeline give specific detail research tibotec therapeuticsthe company marketing development function daytodayand eventually sale clinical arminitiate large clinical hourtohourbasis cover wall tibotec study conduct treatmentexperience adult facility mechelen belgium poster foot long woman hiv grace gender race clinical foot wide poster illustrate interplay experience study compare gender difference function deliverable constant reminder efficacy safety tolerability prezista administer deadline commitment antiretroviral agent week treatment original team member mariepierre de bethune period study conduct site vice president clinical virology say motto mexico canada explore racial patient wait drive work way paul difference treatment outcome call fast possible compromise quality say mchugh woman represent nearly science ethic personal sacrifice meet percent infection worldwide vastly highly accelerate timeline instance highoutput represent hiv clinical trialseven research month restrict vacation time come time date suggest woman tolerate hiv medica work application health authority core team tion different way man suggest certain go offsite remote location northeast belgium complication disease genderspecific entire week work pm day ve work closely hiv community johnson johnson annual reportdeveloping trial grace study collabora provide access medicine say mchugh tibotec tion international partnership microbicide virco believe people need product tmc refl ect deep commitment address hiv ready access find creative way ensure treatment prevention option woman girl access core business well access develop nation receive epidemic sight research early approval prezista company launch development team tibotec virco tibotec global access program initiative hiv sight unique situation create infectious tmc fi rst novel antitb compound year disease global pandemic tibotec discover johnson johnson pharmaceutical antiretroviral available reduced price sustainable research development llc laboratories beerse belgium basis people need country develop tibotec tibotec recently program include early fi le registration prezista obtain codevelopment marketing right select country select basis territory vertex pharmaceutical vx factor include incidence prevalence hivaid promise oral inhibitor hepatitis c virus hcv protease maturity hiv treatment program pre drug call telaprevir early development ence international hiv program dossier addition tibotec internal preclinical hcv drug submit country include discovery program advance hcv protease inhib high hiv burden brazil china india south itor clinical study collaboration medivir ab africa thailand ukraine develop year come say werner verbi general manager country worldespecially subsaharan african virco bvba virology franchise continue explore nationsthe company actively pursue agreement use biomarker diagnostic drug discovery license generic manufacturer purpose seek increasingly personalize eff ective recognize unparalleled challenge pose treatment matter thing aid epidemic responsibility collaborate forefront work international response pandemic particularly patient wait employee volunteer village unfortunately water upgrade ugandan contaminate microorganism cholera tibotec virco employee initiative village water support large volunteer project provide support service mulanda include homebase care counseling hivaid patient tibotec virco offi ce mechelen belgium yardley pa cleanwater project take life employee initiate fundraise effort research lead africa early include car wash photographic contest say jens van roey md director global clinical calendar production sponsor triathlon development tibotec time paul stoffel athletic event sale item water work clinical caregiver bucket tshirt item contribute individual medical researcher zaire congo employee include homegrown fruit vegetable poor country subsaharan africa begin apple juice homemade belgian waffl es notice sign plaguetocome overemphasize volunteerism not vast yettobenamed microbial scourge oneside charity valuable exchange central africa undoubtedly evolve epicenter van roey say twoway streeta constant ensue year country uganda dialogue people teach suffer terrible loss hivaid say live dignity solidarity broad van roey million adult ugandan jens van roey md tibotec virco sense family amid unrelenting ravage disease colleague mechelen belgium help lose epidemic ve leave nearly employee encourage visit mulanda provide ugandan village fresh water million orphan disease invade aspect fi rst employee visit village fall supply child need walk hour lifework home community day collect water employee volunteer van roey serve liaison new employee eye like live hiv africa initiate project begin provide support village mulanda near professional dedication instinctively redouble especially aware ugandas eastern border kenya project focus effort provide critical opinion involved possible early sustainable supply fresh clear water village aim reduce morbidity stage hivaids process help understand hiv pandemic mortality arise poorquality water mulandan child walk hour socioeconomic medical problem need day carry water distant source sick parent adult drug human vs microbe passion transform restore joy life w hen patient christopher act like life party job say markus michel md head physician orthopaedic center munsingen swiss facility worldrenowne prevent correct disorder bodys support structure include skeleton joint muscle ligament cartilage year christopher unmet patient need alfonsi switzerland successful spend initial year depuy indemand djsa highenergy bioengineergoe explain professional expect christopher prime exam party late night end recall ple todays patient dr michel life come young informationempowere grind halt severe hip prob patient engage surgeon lem cause feel unrelenting discussion treatment option disable pain year ago add alfonsi evolve christopher present demographic profile present new word job challenge orthopaedic surgeon mean everythingnow tell patient like christopher life tell work look stateoftheart sur long fun not play gical intervention offer optimal sport anymore function fast recovery give driving say allow patient preserve professional personal relation active lifestyle ship jeopardy bad christopher not remember geographic boundary painfree past depuy utilize multinational feel likeand not begin multidisciplinary team imagine painfree future develop good solution turn christopher change need todays need operation usually hip patient explain professor associate twice graham isaac senior engineering markus michel md head physician switzerland agehe need hip replacement fellow hip believe worldrenowned orthopaedic center munsingen international approach senior hip replacement surgery not research development differentiate depuy senior anymore explain stefano alfonsi worldwide orthopaedic industry involve surgeon bioengineer vice president hip marketing depuy orthopaedics inc manufacturer marketer expertise true collaborative leader develop stateofthe art technology joint effortwith people passion extra mile reconstruction fact orthopaedic patient population continue isaac team global surgeon provide get young patient unwilling accept longterm insight unmet patient need surgical procedure pain want maintain quality life additionally bioengineer draw expertise find technical treatment option young patient expand solution clinical challenge product management johnson johnson annual reportback saddle age christophera swiss djdevelope severe hip problem bring life painwracked halt receive depuy proxima hip implant bike good team responsibly introduce technology market require surgeon cut muscle tendon place focus professional education minimize softtissue damage alfonsi elaborates collaborative product develop depuy asr xl metalonmetal bearing useful ment approach automotive engineer young people good cortical bone tissue design system improvement climb car highperformance bearing large test drive team license diameter facilitate lower wear high joint stability patient test drive surgeon thatso compare traditional bearing high stability rely heavily professional feedback new give patient great level confidence invention efficacy s exactly depuy regularly con return daily activity new technology vene panel surgical opinion leader world introduce europe past year depuy introduce major innovation preserve bone hip replacement surgery dj get groove christopher need highly depuy proxima hip implant device short stable durable joint dr michel choose depuy anatomical stem porocoat porous coating proxima hip combination depuy asr xl specifically design preserve femoral bone soft metalonmetal bear tissue advance hip replacement introduce week operation christopher dj europe investigational device exemption run report dr michel study begin early book party make music drive car depuy proxima hip find perfect synergy keep fit play sport depuy innovation depuy microhip say alfonsi year year high aspiration surgical procedure develop surgeon switzerland help surgeon like dr michel away patient pain minimally invasive surgical technique restore joy life restore joy life passion transform moment life quiet moment silence baby breath grand boardroom chinese ministry health echo joy marini thought wait landmark meeting ministry official organization hope accomplish asphyxia inability breathe birth million difficult climbing great wall think marini ms pac baby bear year challenge director johnson johnson pediatric institute llc jjpi impossible year china nearly newborn look giant mural manmade wonder lose fight life breath deprive oxygen mid chinas ministry health seek long second suffer disability partner address overwhelming challenge affect permanent brain damage live heart million family china worldwide neonatal asphyxia strike ministry want jjpis collaboration help baby bornbut happens difference solve lead cause infant mortality china neonatal baby treat quickly good outcome international partner chinese ministry health beijing li far leave joy marini second leave johnson johnson pediatric institute llc meet chinese ministry health representative ms cao bin second right director child division madame zhang deye deputy director maternal child division discuss chinas neonatal resuscitation program johnson johnson annual reportfew chinese nurse doctor midwive outside urban hospital receive practical handson training intervene neonatal asphyxiauntil ministry determine save future generation child early death heartbreaking disabilities jjpia johnson johnson company dedicate save life mother baby world overthey find equally determined partner breath life year later chinese ministry healths division child health launch neonatal resuscitation program nrp program teach chinese health care worker rescue newborn baby struggle breath life bring wide range health professional range local circumstance deliver thousand baby year china townships county city province include obstetricians pediatrician neonatologist anesthesiologist nurse midwive today jjpis help ministry reach pacific ocean forge partnership american academy wang lixin nurse beijing day help mother pediatric marini say gold standard bring baby world year train neonatal asphyxia wonderful international wang lixin see tragedy unfold baby boy girl fuss collaboration group learn struggle try breath finally turn blue lack oxygen morning wang lixins friend liu jia nurse like drop ink water inception july lie birthing table past year wang lixin ministry healths nrp train teach nurse defeat deathand native health care professional trainer hold hand save live countless baby today resolve wang lixin silently today breath die life prevail come time wang lixin friend year program easily surpass liu jia birth liu lifeand childs lifein goal originally set fiveyear mark nrptraine hand nrptraine peer professional work chinese city wang lixin nrp national trainer personally teach thank largely cadre inspiredand inspiringnurse chinese nurse quickly fan nation voluntarily nation train concentric succession official onechildperfamily drop calligrapher ink fall bowl clear birthing policy heighten water spread say li shanghai expectant parent base representative jjpi serve daytoday dreams anxietie wang contact ministry nrp model work lixin volunteer basis way hardworke nurse see baby baby travel deep eastern live instead die immediately help china teem city involve program find hospital nurse volunteer teach feel firstever glimpse professional life great meaning neonatal rescue train liu jia son yang yang marini say secret chinas nrp spread health professional far fast initiative travel remote outpost nurse work see asian travel encouragement portable infantsize oxygen tent motivation incredible program core value help guide growth nrp nrp task force member key success find time energy fulfill responsibilitie joy true soul mate volunteer capacity president division midwive work ve learn say li chinese nursing association ve cultural guide forge powerful like wang lixin liu jia proud homelands strong crosspacific collaboration new commitment protect newborn infant preventable wake morning not believe ve death illness smile laugh cry lucky work initiative like nrp save precious yang yang future family thankful baby beautiful country say marini train team know exactly bear good job world breathe moment life year review consumer health care pch acquisition make johnson johnson worlds premier consumer health care company groupe vendome acquisition expand global skin care presence new product fuel worldwide growth oral care business seize rare opportunity pfizer consumer healthcare pch acquisition broaden floss brushes acquisition pfizer consumer healthcare asset mark important milestone whitening product history world comprehensive broadly base health care product company consistent longstanding strategy leadership attractive health care market acquisition extend leadership consumer health care category strengthen global reach bring combination consumer business promise sustained growth global basis exus right nicorette visine nonprescription eyecare product world leader smoking cessation complement vision care franchise gain significant entry highpotential segment lubriderm moisturizing product expand adult skin care franchise combination pfizer listerine antiseptic worlds johnson johnson oral mouthwash transform oral care neosporin complement care business create business billionplus franchise woundcare business expand presence market billionplus franchise benadryl sudafe expand fourthlargest oral care business otc upperrespiratory business world listerine mouthwash brand nutritional business continue turn recipe success world johnson johnson hold position way say thank loyal consumer toothbrush globally splenda sucralose america favorite sweetener new product reach mcneil nutritional llc introduce official cookbook clean whiten toothbrush splenda world sweetness create response reach inbetween toothbrush enormous consumer demand splenda world position dental sweetness provide family tool create reduced floss include new reach sugar lowercalorie version favorite food cleanpaste floss beverage compromise sweet taste position whiten mcneil nutritional llc introduce product introduction splenda brand flavor blend coffee splenda brand quick pack pouch rembrandt whitening strip unsweetene powdered drink mix viactiv calcium soft chew teen premium mint flavor new extra strength tylenol bandaid brand compeed cortaid le petit marseillais stayfree dry max carefree large acetaminophen adhesive bandage cold sore patch poison ivy care kit shower gel soap ultra thin maxi europe gotabs antibiotic bandage europe treatment kit bath hair care product north america products johnson johnson annual reportjohnson soothe natural line expand consumer segment sale company underscore sale major franchise commitment mom sale million growth rate year johnson baby million dollar brand indispensable partner baby kid care womens health mom product line fragrance extend traditional brand online effort underscore commitment new generation mom johnson soothe natural breakthrough collection baby skin care product feature natural ingredient expand europe africamiddle east asiapacific region product combine gentleness johnson heal power nature skin care available end johnson baby lotion fragrance extend baby wash cream babycenter wwwbabycentercom redesign include technology otc advancement enhance commerce pharmaceutical nutritional platform reestablish preeminent online destination mom science lead bath hair care product aveeno skin care product laboratory vendome scientific way growth dermatologicalsolution innovation evident skin care brand body cleanser new product moisturizer primage clean clear baby toiletry brand oxygenate skincare line skin care business emphasis bring clean clear grow strong superior science skin care advantage invisible consumer receptivity evident number acne patch scientific innovation strong new product introduction ambi clear professional support skin care new line advanced skin increase penetration business include care product help woman international market new patent ingredient african latin south line product contain geographic expansion provide strong asian heritage achieve clear naturally calm active skin care business protection available eventoned skin natural feverfew enhance sun harmful uva neutrogena mineral nourishing renewal lotion acquisition ray cause skin cancer sheer pure gentle nourish care groupe vendome french photoage makeup formulate hour moisturizing wash company know adult brand helioplex mineral innovation prompt baby skin care brand technology neutrogena aveeno ultracalme relaunch johnsons le petit marseillais skin care product active shave gel new softlotion line shower gel soap photobarri complex aveeno ultracalme softwash adult carefree healthy fresh ky brand ky brand ky brand splenda splenda viactiv calcium liner wash sensual mist touch massage touch massage brand flavor blend brand quick pack soft chew teen asia pacific warming nonwarme warm personal massage lotion line extension coffee pouch unsweetene mistable lubricant plus personal lubricant powder drink mix year review year review pharmaceutical new prescription medicine approve new growth platform virology launch important new indication lead rxs inlicensing add new product pipeline nearterm pharmaceutical diagnostic strength pipeline combine new virology franchise communicate june fda grant conditional marketing authorization investment community plans file accelerate approval prezista receive european commission secure approval darunavir know tmc february new molecular entity nme treatment hivaids nearterm pipeline end nmesprezista antiretroviral arv experienced virology hold latestage ionsys jurnista eu adult pharmaceutical hiv medicine invegawere approve business launch tmc phase iii fifth doripenem file hiv treatment launch investigational nnrti performance track entire new growth engine virology significant activity patient prior seven additional filing expect business devote fight nnrti failure end world deadly disease tmc phase iib dosefinde study project filing january launch important new potent nnrtis cns paliperidone virology franchise begin year early develop potential palmitate acquisition promise young backbone range fixeddose carisbamate belgian company tibotecvirco combination today tibotec pharmaceutical ltd tibotec virology franchise pain tapentadol therapeutic division ortho biotech earlystage development effort imid cnto product lp virco bvba backbone complementary inlicensing focus cnto highly innovative virology business hepatitis c hcv tuberculosis tb oncology zarnestra base evolve science combine respiratory syncytial virus rsv pharmaceutical diagnostic approach clinical datum tmc dacogen eu thank strong internal development tb patient present yondelis capability inlicense important tmc potential virology tmc earlystage product virology franchise new tb drug year telaprevir eu launch strong pipeline emerge profile appear promise growth year come attractive licensing agreement antibacterial doripenem prezista potent protease inhibitor vertex pharmaceutical ceftobiprole demonstrate significant activity vx call telaprevir add cardiovascular rivaroxaban wildtype drugresistant promise novel protease inhibitor urology dapoxetine strain hiv expert field agree treatment hcv virology select eu drug offer new hope treatment pipeline virology franchise hematology ica experience patient prezista work close partnership vertex arv decade receive fda accelerate development important est file est filing approval base phase iib datum phase iii molecule commercial right est filing file study early experience treatment outside telaprevir currently carisbamate licensed skbio pharmaceutical naive patient ongoing form phase iib treatment adult doripenem licensed shionogi co tapentadol license grunenthal gmbh yondelis license traditional filing year chronic hcv hepatitis c blood pharmamar ceftobiprole license basilea pharmaceutica rivaroxaban license bayer healthcare ica approval grant borne liver disease cause infection license icagen dacogen license mgi pharma canada russia argentina switzerland hepatitis c virus telaprevir license vertex pharmaceuticals inc dapoxetine license ppdgenupro johnson johnson annual reportorthomcneil inc pharmaceutical segment sale sign deal sale major product worldwide right sale million growth rate million dollar type diabetes risperdal risperdal consta compound license agreement orthomcneil inc procrit metabolex inc eprex yield investigational compound currently clinical development treatment type diabete orthomcneil secure exclusive world hormonal contraceptive wide development commercialization right remicade metabolex compound represent aciphex pariet novel class insulin sensitizer duragesic inlicense add topamax fentanyl levaquin transdermal product rx floxin pipeline detail page new atypical satisfy unmet need risperdal consta long adolescent aged year treatment act injection continue antipsychotic schizophrenia perform strongly additional dosage strength reinforce daily oral medication mostprescribe mg mg specifically design deliver fastestgrowe treatment risperdal mtab fast leadership paliperidonethe active schizophrenia dissolve form risperdal psychiatry metabolite risperidone risperdal risperidone innovative oros medication available prescription extendedrelease technology approve fda convenient delivery form longstanding leadership demonstrate powerful treatment irritability make take medication position disease efficacy clinically prove associate autistic easy patient central nervous system cns safety tolerability profile disorderinclude dissolves second specifically psychiatry longacte formulation symptom aggression place tongue strengthen contain paliperidone deliberate selfinjury temper alternative patient fda palmitate tantrum quickly change difficulty like approval invega far moodsin child swallow pill paliperidone johnson johnson rnai pioneer craig mello name inaugural winner extendedrelease pharmaceutical dr paul janssen award biomedical research tablet new research atypical antipsychotic development llc new award establish johnson johnson honor dr paul janssen treatment expect file new th century innovative inspire pharmaceutical schizophrenia drug application researcher founder janssen pharmaceutica present important approval paliperidone palmitate inaugural recipient craig c mello phd role discovery rna risperdal risperidone administer injection interference rnai elucidation biological function dr mello treatment irritability week professor molecular medicine university massachusetts associated autistic end medical school worcester mass investigator howard disorder hughe medical institute shortly dr mello colleague invega represent risperdal risperidone andrew fire stanford university award nobel prize important step forward franchise risperdal physiology medicine discovery year review remicade new pain medicine grant significant novel delivery system approve indication new pain medication skin dose pain relief single approve use deliver minute dose jurnista launch novel drug delivery period ionsys germany denmark system develop alza product slovenia slovakia corporation manage incorporate proprietary schedule launch moderate severe pain etran iontophoretic european country ionsys fentanyl transdermal drugdelivery register iontophoretic transdermal system develop alza market janssen remicade infliximab centocor system needlefree corporation iontophoresis cilag company inc biologic immune mediate patientactivate analgesic process low world inflammatory disorder garner intensity electric field addition significant new indication generally imperceptible prescription pain medication remicade world patient approve pricara versatile biologic total rapidly transport fentanyl unit orthomcneil inc approve indication ie unique patient skin biovail corporation population range rheumatoid circulatory system launch ultram er arthritis plaque psoriasis system approve tramadol hci extend approve efficacy claim united states release tablet remicade approve europe expect extend pediatric crohns disease launch second half release tramadol product inhibition progression ionsys indicate market structural damage improve shortterm management look ahead pain physical function psoriatic arthritis acute postoperative pain jurnista prolonged pipeline johnson johnson treatment chronic severe plaque adult patient require release tablet hydro pharmaceutical research psoriasis adult expand opioid analgesia morphone hcl new development llc maintain longterm clinical remission hospitalization ionsys prescription treatment hope file new mucosal healing patient compact selfcontaine severe pain develop drug application moderate severely active system deliver alza corporation tapentadol centrally ulcerative colitis remicade demand pain medication utilize oros push act analgesic co global market leader antitnf therapy need patient pull delivery system develop grunenthal remicade receive patient doubleclick delivery technology release plan tapentadol regulatory approval major dose button system opioid hydromorphone immediaterelease indication european country deliver preprogrammed consistent rate providing extendedrelease major new indication dose fentanyl patient hour formulation canada numerous approval rest world licensing deal enhance oncology growth engine centocor exciting nearterm product cnto nextgeneration antitnf antibody licensing deal recently ortho biotech product lp supplemental likely emerge bestinclass enhance pharmaceutical growth enter new agreement new drug application doxil product initially study engine oncology foundation millennium jointly promote velcade combination therapy rheumatoid arthritis psoriatic arthritis procriteprex epoetin alfa usbase physician treat velcade treat patient ankylose spondylitis doxil doxorubicin hcl liposome mantle cell lymphoma multiple multiple myeloma disease explore wide range injection deal reinforce myeloma patient received progress relapse prior therapeutic area fully human commitment deliver innovative prior therapy therapywa submit review antibody develop effective treatment cancer patient addition see janssencilag fda janssen pharmaceutical subcutaneously intravenously unmet medical need license mgi pharma global kk gain approval velcade administer product long care development commercialization japan dose intervalsunique class international right outside north america nearterm pipeline centocor develop novel janssencilag business market dacogen decitabine injection oncology include promising immunomodulator cnto lead treatment multiple treatment myelodysplastic drug yondelis trabectedin firstinclass antiil cnto myeloma velcade bortezomib syndromes mds disease bone codevelope pharmamar phase iii trial psoriasis novel protease inhibitor marrowwhich currently phase iii subsidiary zeltia group demonstrate new use codevelope trial europe mgi pharma receive zarnestra tipifarnib strong efficacy millennium pharmaceuticals inc approval dacogen acute myeloid leukemia aml johnson johnson annual report year review medical device diagnostic new product extend global leadership medical technology major acquisition expand key business portfolio cordis corporation portfolio benefit transform diabete care acquisition agreement rd measurement management strategic acquisition licensing transaction strengthen cordis global leadership position lifescan inc focus similarly onetouch interventional cardiology strategic move horizon blood glucose business area transaction simple blood glucose monitor specifically contribute new product introduction measurement diabete design provide great franchise year management order access testing develop acquisition ensure medical inc deliver improve patient health market india privately hold company sunnyvale calif develop outcome currently percent device postcatheterization closure femoral artery offer patient provider million people expand cordis presence california tool well insight diabetes monitor launch accelerate medical venture stateofthe disease management blood glucose patient art advanced research development facility san onetouch ultra market require francisco bay area blood glucose monitor simple discrete affordable johnson johnson acquisition help patient link effect testing offer conor medsystem inc complete february food blood glucose result onetouch horizon monitor expect complement exist drugeluting stent lifescan inc offer acquisition business unique control drugdelivery technology product provide great animas corporation acquisition provide access blood glucose company specialize cordis portfolio unique drugdelivery monitoring develop insulin delivery system continue grow addition dozen new technology explore develop market key development product include range therapeutic new onetouch ultramini johnson johnson diabete category blood glucose monitor franchise lifescan animas cypher select plus immediately contributes market onetouch work provide generation drugelute stent launch development ultraeasy country superior range integrate major global market generation technology offer basic testing solution insulin delivery japan aim advance small affordable simple blood glucose monitoring carto rmt v niobe integrate standard care touse monitor encourage simplify diabetes control electroanatomical navigation system treatment cardiac appropriate testing great patient insulin precise nitinol stent vascular disease glucose control health care professional angioguard emboli capture distribution guidewire cordis sign distribution agreement brivant ltd interventional guidewire product market umbrella brand know regatta cordis sign agreement clearstream technologies group plc distribution right crescendo ptca percutaneous transluminal coronary angioplasty balloon dilation catheter country japan canada addition biosense webster inc cordis franchise secure exclusive worldwide right distribute siemen medical solution stateoftheart cardiac catheter acuson acunav ultrasound catheters electrophysiologists year review ethicon inc medical device diagnostic segment sale continue pioneer minimally invasive sale major franchise sale million growth rate surgical advance million dollar woman depuy ethicon ethicon inc introduce important advance er minimally invasive alternative ethicon endosurgery common surgery cordis woman gynecaretvt securabove new midurethral sling treat female stress urinary incontinence feature small mesh implant lifescan skin exit incision orthoclinical diagnostic gynecare morcellex vision care tissue morcellator facilitate laparoscopic supracervical hysterectomy lsh preserve ethicon endosurgery inc cervix new surgical tool design minimize launch new surgical innovation challenge physician face ethicon endosurgery inc mammotome mr bladeless probe perform procedure introduce surgical innovation target set breast biopsy system gynecare morcellex round portfolio er new use mri imaging facilitate technology nearly procedure addition advanced sterilization laparoscopic myomectomy perform general bariatric product division ethicon inc procedure uterine gynecological surgeon new product receive fda clearance evotech fi broid remove include harmonic wave open shear endoscope clean reprocessor ecr ethicon mm late innovation fi rstever washerdisinfector eliminate acquisition vascular ultrasonic energy open surgery harmonic requirement manual cleaning control systems inc ace open scissor code contour endoscope add innovation transtar curved cutter stapler procedure high volume new product womens health portfolio set staple transanal rectal resection introduction demonstrate ethicon endo primary technology starr echelon endopath stapler surgerys commitment transforming gain uterine artery long endopathxcel bladeless mm patient care innovative medical occlusion treatment bariatric surgery ligamax endoscopic device minimally invasive open ethicon develop multiple clip applier endopath etsflex surgical procedure lessinvasive treatment articulate endoscopic linear cutter fi broid fi broidrelate symptom ethicon introduce ultrapro hernia system uhs surgiflo hemostatic matrix flextip ethicon omnex surgical sealant europe johnson johnson annual reportdepuy orthopaedics inc evolve minimally invasive vistakon vistakon division technique sport medicine introduce johnson johnson vision broaden leadership orthomedic south african care inc continue perform new advance acquisition distributor expand company strongly globe vision care presence region new product introduce portfolio development include day acuvue addition depuy capitalize moist brand contact lense learning charite day acuvue define artificial disc extend vivid style cosmetic contact strategic acquisition spine portfolio introduction lense asian market internally develop innovation discover cervical disc story depuy franchise europe late comprehensive orthopaedic patient enrol orthoclinical diagnostic inc receive fda approval business span entire clinical trial july lifetime continuum orthopaedic bloodscreening test chaga disease carefrom sport medicine early intervention joint replacement spinal fusion chaga disease call chagas disease strategic acquisition american trypanosomiasis test approve continue broaden depuy infection cause fda use leadership important category parasite trypanosoma cruzi centers disease impact future development year new innovation cruzi damage control prevention meaningful innovation age hip replacement introduce heart tissue cause death cdc estimate population depuy proxima bone disease endemic million people worldwide hand innovation llc privately preserve hip implant europe country central infect chaga hold manufacturer widely young demand south america disease fracture fixation product patient depuy asr xl mexico transmission die year chagas disease upper extremity provide lead metalonmetal large head occur insect bite treat successfully technology plate fast hip bearing launch blood transfusion detect soon grow underpenetrate continue gain usage organ transplant infection occur segment trauma market story infect pregnant woman cure disease future medical system sa depuy mitek see child utero new enter chronic privately hold company use milagro bioreplacable test orthoclinical stage test primarily develop manufacture screw rapidly expand year diagnostic inc call implement market arthroscopic fluid postlaunch important indicator ortho cruzi elisa test increase prevalence management system position physician adopt system design screen blood donor depuy forefront rapidly technology blood donor exposure improve transfusion safety veridex llc introduce second novel diagnostic platform year orthoclinical diagnostic inc add new assay menu veridex llc recently advisory panel review claim aid vitros eciq assay include launch second december monitor metastatic test aid diagnosis novel diagnostic platform platform breast cancer cellsearch congestive heart failure year genesearch cellsearch system new genesearch determine patient world genebase identifie enumerate breast lymph node diagnostic previous ongoing diagnostic test design circulate tumor cell ctcs test represent infection hepatitis detect spread breast directly blood chapter invitro diagnostic virus hav quantify level cancer lymph node breast cancer patient story oncology marker use molecular technology approve orthoclinical aid assessment diagnose stage january diagnostic diagnostic inc expand metabolism new vitro accurately characterize tumor tool identify diagnostic menus microtip chemistry product surgery count ctcs blood new fdaapproved include test detect guide procedure sample predict progression assay include assay presence drug abuse genesearch enter free survival overall vitros eciq measure homocysteine european market mid survival patient immunodiagnostic system concentration blood compliance eu vitro metastatic breast cancer new microtip plasma measure extent medical device regulation cellsearch grant assays vitros fs redblood destruction receive favorable fda expand fdaapproved chemistry system new manage diabete year review year review caring environment reduce reduce january environmental begin new set carbon dioxide fiveyear sustainability impact goal healthy planet emission goal continue require grow sale year government johnson johnson family track common johnson johnson take company strive environmentalfootprint seriously challenge reduce environmental indicator like water global climate change earn fifth impact operation energy waste apply sustain long product example go consecutive term action address total water improve environmental grow threatinclude green power use normalize sale profile product adoption climate decrease percent increase employee leadership award friendly energy policy correspond environmental literacy take aggressive percent absolute reduction increase johnson johnson measures reduce carbon water use addition paper packaging company earn award dioxide emission period total waste source sustainably environmental percent absolute generation normalize manage forest protection agency basis sale decrease percent set sustainability consecutive year period sale correspond goal review participation voluntary increase percent percent absolute reduction wwwjnjcom green power partnership set continue program foster development trend currently green power market percent electricity partner partner operate company rank need come green manner consistent thirdlarg corporate power source solar energy value help purchaser fifthlarg wind energy biomass supply chain partner clearly purchaser geothermal source stand expectation external manufacturing develop partner protect ecosystem continue critical consideration aspect achieve different legal cultural special responsibility johnson johnson environment leadership growth external manufacturing johnson johnson support wildlife fund wwf objective partner operate number nonprofit make environment publish standard internationally recognize organization engage healthy sensitive responsible external expectation business restore preserve ecoregion wwf manufacture ethic product quality labor fragile ecosystem healthy community healthy standard help select employment health include conservation ecosystem program external manufacturing safety environment fund trust public improve community health land nature conservancy area include kenya guide principle external manufacturer wilderness society mozambique kenya new particularly interested dispensary construct comply applicable promote safety health community health project allow great access legal requirement wellbee employee directly link sustainably medicine safe drinking behave ethically operate environmentally manage environment water provide integrity responsible manner need access health care mozambique new integrate quality implement management community live near fishing sanctuary business process system ensure ongoing area high biodiversity create health clinic treat people dignity performance continual signature congo basin staff respect improvement partnership world equip johnson johnson annual report year review give world century giving building health care mark milestone disaster relief philanthropic outreach company history commemorate th continue today world reflect capacity anniversary document response credo commitment community major disaster aftermath live work earthquake strike san francisco highlight philanthropic effort johnson johnsonucla provide medical product set take world management development field hospital support relief effort find effort institute africa institute program intensive management action set motion legacy wwwjnjcom training health care keep mother health care system leader east african facilities cameroon china organization provide hiv child dominican republic india aids prevention treatment care healthy russia zimbabwe support service seventy health leader seven african project mercy nation train prematurity prevention medhanealem school initiative ethiopia provide hospital management partnership march hivaids education training project china dimes kentucky orphan support resident ongoing program department public health uneducated rely equip hospital administrator test bundle prove heavily simple condition management tool intervention low rate routine survive competency necessary preventable preterm birth support doctor provide quality patient care project mercy ethiopia glen c olsen hospital train everchange health care elizabeth glaser students public health success national environment administer pediatric aids foundation issue sexually safe kid campaign china hospital management worldwide partner transmit disease malaria start association support johnson johnson prevention intestinal see dramatic decline xianjanssen pharmaceutical ltd prevention parasite educate childhood injury death mothertochild transmission influence village rate inception european health leadership hiv pmtct celebrate th anniversary programme europe partnership reach safe kid worldwide safe kid worldwide partnership insead pregnant woman foster multifacete initiative active country johnson johnson hiv testing counsel global scale base major continent bring participant country twoweek provide improve access continue educational experience equip relief help communitie health care concept tool disaster strike southern affect health product technique strategy play hurricane katrina significant leadership role effort include assistance mebendazole donation health care respond product establish mental initiative cameroon money follow health program new multiyear program associacao saude de major disaster child traumatize provide mebendazole familia brazil train outreach include mudslide disaster funding treatment intestinal worker provide hivaid philippine automatic electronic worm health education female earthquake indonesia defibrillator key severely infect adolescent adult woman johnson johnson community health center child world partner dozen affiliate provide local new orleans support million dose health team assistance immediate university distribute use train nearly aftermath disaster educational service cameroon woman benefit year review board director row leave right william c weldon chairman board directors chief executive officer christine poon vice chairman board directors michael e johns md executive vice president health affairs emory university chief executive officer robert w woodruff health sciences center emory university chairman emory healthcare emory university second row leave right ann jordan director social services department chicago lyingin hospital leo f mullin retire chairman chief executive officer delta air lines inc mary sue coleman phd president university michigan row leave right david satcher md phd director center excellence health disparity morehouse school medicine surgeon general susan l lindquist phd member director whitehead institute biomedical research professor biology massachusetts institute technology steven reinemund executive chairman pepsico inc fourth row leave right james g cullen retire president chief operating officer bell atlantic corporation arnold g langbo retire chairman chief executive officer kellogg company charles prince chairman chief executive officer citigroup inc johnson johnson annual reportcommittee nomination corporate governance nominate corporate governance committee board comprise entirely independent director responsible oversee corporate governance matter review possible candidate board membership recommend nominee election committee responsible overseeing process performance evaluation board committee additionally committee review company management succession plan executive resource audit audit committee comprise entirely independent ann jordan chairman director help board oversee company accounting jame g cullen reporting practice recommend independent public arnold g langbo accountant appointment board review charle prince performance monitor adequacy internal accounting steven reinemund practice procedure control review significant change accounting policy public policy jame g cullen chairman public policy advisory committee review company mary sue coleman phd policy program practice public health issue leo f mullin environment health safety employee committee review company governmental affair policy public policy compensation benefit issue face company committee advise make compensation benefit committee comprise recommendation board issue appropriate entirely independent director reviews compensa public policy advisory committee comprise tion philosophy policy nonboard management independent director companys general counsel compensation committee respect executive vice president corporate affair government compensation perquisite compensation matter affair policy employee member executive committee committee administer company leo f mullin chairman longterm incentive plan determine compensation russell c deyo members executive committee additionally thomas gorrie phd committee oversee management susan l lindquist phd retirement pension longterm incentive saving health brian perkin welfare plan cover substantially employee david satcher md ph company domestic operation employee certain international subsidiary science technology arnold g langbo chairman science technology advisory committee comprise michael e johns md independent director company vice president ann jordan science technology advise board scientific charles prince matter include major internal project interaction steven reinemund academic outside research organization acquisition technology product finance david satcher md phd chairman finance committee exercise management authority mary sue coleman phd board interval board meeting michael e johns md finance committee comprise chairman susan l lindquist phd presiding director vice chairman board theodore j torphy phd william c weldon chairman james g cullen christine poon board director committee board corporate officer william c weldon thomas gorrie phd theodore j torphy phd chairman board directors vice president vice president chief executive officer government affair policy science technology chairman executive committee joann heffernan heisen nicholas j valeriani christine poon vice president diversity worldwide chairman vice chairman board director medical device diagnostic group executive committee david p holveck executive committee vice president dominic j caruso corporate development vice president finance chief financial officer raymond c jordan executive committee executive committee vice president public affairs johnson johnson principal corporate communication management group responsible stephen j cosgrove operation allocation corporate controller john papa resources company treasurer committee oversee laverne h council coordinate activitie vice president chief brian perkin consumer pharmaceutical information officer vice president medical device corporate affair diagnostic business segment russell c deyo subsidiary vice president general counsel steven rosenberg business segment chief compliance officer secretary exception manage citizens executive committee assistant general counsel country locate kaye fostercheek joseph c scodari vice president human resource worldwide chairman executive committee pharmaceutical group executive committee colleen goggin worldwide chairman ajit shetty johnson johnson consumer group vice president executive committee worldwide operation company group chairmen rick anderson john h johnson kristine peterson supratim bose guy j lebeau md marc e robinson donald casey karen licitra jose v sartarelli phd rosemary crane sheri mccoy michael e sneed roy n davis julie h mchugh pericle p stamatiade seth h z fischer patrick mutchler paul stoffels md carlos gottschalk david norton johnson johnson annual reportcorporate governance management responsibility johnson johnson govern value set forth pricewaterhousecooper llp independent register credo create general robert wood johnson public accountingfirm engage perform integrate audit principle guide year continue set consolidated financial statement internal control tone integrity theentire company level financial reporting report independent register employee johnson johnson commit tothe ethical public accountingfirm onpage principle embody credo principle theaudit committee board director compose woven fabric company solely independent director financial knowledge thevalue articulate credo extend account experience provide appropriate oversight review internal ing financial responsibility johnson johnson share control matter key accountingand financial reporting issue holder investor management johnson audit committee regular basis addition johnson responsible theintegrity objectivity independent auditor general counsel vice presi accompany financial statement relate information dent internal audit regularly meet private session responsible ensuringthat financial datum report audit committee discuss result work include accurately manner facilitate understand observation adequacy internal financial control thisdata quality financial reporting confirmation prop evidence commitmentto responsibility erly discharge responsibility relevant matter maintain welldesigned system internal accountingcon executive committee continuously involve trol encourage strong effective corporate governance thereview financial result develop board director continuously review business result stand strategy key initiative longterm growth strategic choice focus financial stewardship intentis ensure maintain objectivity business corporate staff professionallytraine internal audi assessment constructively challenge approachto business torswho travel worldwide monitor system internal opportunity issue monitor business result accounting control design provide reasonable assurance relate control asset safeguard transaction event consolidate financial statement financial datum record properly internal control include selfassessment follow prepared conformity accounting internal review operating company principle generally accept united states america company continuedto invest significant include amount base good judgment time resource order ensure compliance section commit present discuss result operation sarbanesoxley act base work clear transparent manner order provide timely com form conclude internal control finan prehensive understandable information shareholder cial report effective december refer management report internal control financial reporting require management team operate company certify compliance policy william c weldon dominic j caruso business conduct systematic program design chairman board vice president finance ensure compliance policy view policy director chief chief financial officer onbusiness conduct visit website executive officer wwwjnjcomourcompanypolicie table content management discussion analysis audit consolidated financial statement organization business segment consolidate balance sheet result operation consolidated statement earning analysis sale business segment consolidate statement equity analysis consolidate earning provision consolidate statement cash flow fortaxe income note consolidated financial statement liquidity capital resources management report internal control information financialreporte cautionary factor affect future result report independent register public accountingfirm summary operation statistical data shareholder return performance graph reconciliation nongaap financial measure johnson johnson annual report management discussion analysis result operation financial condition organization business segment acceptance company consumer product involve signif icantexpenditure advertise andpromotion description company business segment johnson johnson subsidiaries company management objective approximately employee worldwide engage primary objective company achieve superior level research development manufacture sale broad range capital efficient profitablegrowth accomplishthis product health care field company conduct busi company management operate business consistent ness virtually country world primary focus certain strategic principle prove successful product relate human health wellbeing time end company participate growth area thecompany organize business segment human health care commit attain leadership consumer pharmaceutical medical device diagnos position growth segment developmentof tic theconsumer segment include abroad range product innovative product service new product introduce baby kid care skin care oralcare woundcare past year account sale women health care field nutritional billion sale invest research thecounter pharmaceutical product theseproduct mar development increase billion kete principally general public sell increase reflect management commitmentto importance wholesaler directly independentand chain retail outlet ongoingdevelopment new anddifferentiated product world thepharmaceutical segment include service sustain longterm growth product thefollowe therapeutic area antifungal anti operate company locate infective cardiovascular contraceptive dermatology gastroin country thecompany view principle decentralized man testinal hematology immunology neurology oncology pain agement asset fundamental success broadly management psychotropic central nervous system urology base business foster entrepreneurial spirit combin virology area theseproduct distribute directly ing extensive resource large organization retailer wholesaler health care professional prescrip ability react quickly local market change challenge tion use general public themedical device diag thecompany commit develop global business nostic segment include broad range ofproduct leader drive growth objective business man principally professional field byphysicians nurse thera aged thelong term order sustain leadership position pist hospital diagnostic laboratory clinic theseprod achieve growth provide endure source value uct includecordis circulatory disease management product shareholder depuy orthopaedic joint reconstruction andspinal care prod unifying management team company dedi uct ethicon woundcare women health product cat employee achieve objective credo ethicon endosurgerys minimally invasive surgical product credo provide common set value serve constant lifescan blood glucose monitor andinsulin delivery reminder company responsibility customer product orthoclinical diagnostic professional diagnostic employee community andshareholder thecompany product andvision care disposable contact lense believe basic principle itsoverall mission thecompany structure base principle improve quality life peopleeverywhere enable decentralize management theexecutive committee johnson johnson continue beamong leaders johnson johnson principalmanagement group respon health care industry sible theoperation allocation resource company committee oversee coordinate activi tie consumer pharmaceutical medical device result operation diagnostic business segment subsidiary analysis consolidate sale business segment exception manage worldwide sale increase billion com citizen country locate pare increase product line company compete sale increase consist follow company large small locate world competition strong product line regard sale increase thenumber andsize compete company involve com volume petition inresearch involvingthe development improve price ment ofnew exist product andprocesse particularly currency significant thedevelopment new improved product total important company success area business include protect company portfolio intellec sale company billion billion tual property thecompetitive environment require substantial billion represent increase investment continuingresearch multiple sale force sale inter inaddition development maintenance customer national company billion billion billion represents increase johnson johnson annual reportu estimate fiscal fourth quarter growth rate international sale enhance approximately year approximately year thenet earning impact theadditional week billion dollar wasnegligible international sale segment inbillion dollar consumer pharmaceutical medical device anddiagnostic thefiveyear compound annual growth rate worldwide international sale respectively thetenyear compound annual growth rate worldwide international sale respectively analysis sale business sale segment geographic region consumer segment consumer segment sale billion increase inbillion dollar operational growth accountingfor total growth positive currency fluctua europe westernhemisphere tion consumer segment sale billion excludingus increase international sale billion asia pacific africa increase result operation currency fluctuation consumer segment sale growth lead strongsale performance skin care baby kid carefranchise overthecounter otc pharma ceutical nutritional franchise sale billion international geographic region experience sale increase growth lead success growth consistingof europe relaunch tylenolupper respiratory product western hemisphere exclude asia line product containingphenylephrine instead pseu pacific africa region thesesale increase include impact doephedrine growth splendano calorie sweet currency fluctuation dollar foreign ener partially offset sale decline adult currency positive impact europe analgesic theskin care franchise sale bil thewestern hemisphere exclude negative lion represent increase impact asiapacific africa region attributable sale growth aveeno johnson company acustomer adult suncare newly acquire groupe vendme adult represent total revenue sale skin care product line thebaby kid care franchise sale cardinal health mckesson account grow billion stronggrowth lead total revenue respectively success ofpowd product line international market result benefit inclusion rd week cleanser lotion cream product line note annual closing date detail thecompany major consumer franchise sale change dollar million vs vs otc pharmaceutical nutritional skin care baby kid care womens health total management discussion analysis result operation financial condition international market thewomen health franchise sale thetreatment irritability associate autistic disorder grow billion result solid contri child adolescent risperdalcompound patent bution kyand stayfreeproduct line sale schedule expire december company franchise grow billion submit pediatric datum fda order extend exclu primarily acquisition rembrandtbrand sivity june expiration product patent oral care product typically result loss market exclusivity result theoperate result consumer healthcare business significant reduction sale acquire pfizer inc december report procritepoetin alfa eprexepoetin alfa company financial statement begin combined sale billion decline com result subsequent acquisition date notsignificant pare prior year procritexperience sale decline consumer segment sale billion dueto competitor anticompetitive contracting strategy increase operational growth account oncology clinic eprexsale increase total growth positive currency approval weekly administration recent restora fluctuation consumer segment sale billion tion thelabel subcutaneous administration eprexin anincrease international sale billion europe result volumegain eprexpatent increase result operation expire mostmajor european market erythropoietin prod currency fluctuation uct approve biosimilar regulatory pathway consumer segment sale billion increase company filing pathway operational growth accounting forof filing review thecompany predict total growth positive currency impact product beapproved sale increase international sale increase remicadeinfliximab biologic approve operational gain positive currency treatment crohns disease ankylose spondylitis psoriatic impact arthritis ulcerative colitis use thetreatment rheumatoid arthritis achieve sale billion growth pharmaceutical segment prior year continue growth drive increase pharmaceutical segment sale billion demand expand indication fiscal increase change quarter remicadereceive fda approval operational growth remain increase relate treatment adult chronic severe plaque psoriasis positive impact currency pharmaceutical segment topamaxtopiramate approve sale billion increase international adjunctive monotherapy use epilepsy pharmaceutical segment sale billion increase prophylactic treatment migraine achieve billion include operational growth sale increase prior year themigraine relate thepositive impact currency indication key driver sale growth risperdalrisperidone medication treat levaquinlevofloxacin floxinofloxacin symptom schizophrenia bipolar mania risperdal achieve combined sale billion represent constarisperidone long act injection treat growth prior year growth achieve despite symptom schizophrenia achieve billion sale lack growth market increase prior year sale growth wasposi duragesicfentanyl transdermal fentanyl transdermal tively impact low rebate risperdaland high system sale decline billion reduction demand risperdalconsta sale risperdal decline resultof impactof generic andrisperdalconstaincrease billion competition theus certain international market generic whileinternational sale increase billion competition begin january october company receive approval thehormonal contraceptive franchise sale decline food drug administration fda market risperdalfor billion reduction ortho major pharmaceutical product revenue change dollar million vs vs risperdalrisperidonerisperdalconstarisperidone procriteprexepoetin alfa remicadeinfliximab topamaxtopiramate levaquinfloxinlevofloxacinofloxacin duragesicfentanyl transdermal fentanyl transdermal system aciphexparietrabeprazole sodium hormonal contraceptive total johnson johnson annual reportevranorelgestrominethinyl estradiol contraceptive pharmaceutical segment sale billion patch approve fda experience significant decline increase change sale result label change negative medium coverage operational growth remain increase relate concern product safety thesale decline result positive impact currency pharmaceutical segment continue generic competition oral contraceptive growth sale decrease international pharmaceutical seg ortho tricyclenlo norgestimateethinyl estradiol ment sale increase include operational low dose oral contraceptive partially offset sale decline growth relate thepositive impact currency hormonal contraceptive franchise pharmaceutical segment sale billion concertamethylphenidate hcl product increase operational treatment attention deficit hyperactivity disorder achieve growth positive currency fluctuation sale billion represent increase pharmaceutical segmentsale increase inter original concertapatent expire national pharmaceutical segment sale grow new concertapatent issue include operational growth relate expire present fda notapprove generic positive impact currency version substitutable concerta abbreviate new pharmaceutical segment sale include drug application anda generic version concerta benefit adjustment relate previously estimate perform pende approve time ance base rebate allowance manage care contractsthese natrecornesiritide product thetreatment adjustment salesin patient withacutely decompensate congestive heart failure dyspnea rest minimal activity experi medicaldevicesand diagnostic segment ence significant decline demand negative medium cov themedical device diagnostic segment achieve sale erage meta analysis select historical clinical billion represent increase prior trial thecompany believe datum support year operational growth negative conclusion medical consumer publication impact currency sale billion currently approve label natrecorreflect available increase international sale billion datum date increase operation negative natrecorwas purchase company currencyimpact result record intangible asset depuy franchise achieve billion sale amortize year remain unamortized intangible increase prior year growth prima value associate natrecorwa billion endofthe rily depuy orthopaedic joint reconstruction product fiscal fourth quarter base current estimate mitek sport medicine product trauma business project future cash flow adjustment intangible asset acquisition future medical system sa hand innovation require company currently conduct clinical llc contribute growth trial natrecor outcome predict cordis franchise achieve sale billion impact projection future cash flow increase sale cyphersirolimuselut company receive fda approval ingstent large product cordis franchise relatively prezistadarunavir antihiv medication invega flat relatively modest growth cyphersirolimuselute paliperidone extendedrelease tablet new atypical antipsy stent sale cause low average selling price negative chotic thetreatment schizophrenia additionally medium regulatory focus concern drug eluting stent ionsysfentanyl iontophoretic transdermal system correspond lack market growth strong needlefree patientactivate analgesic system receive fda performance biosense webster endovascular busi european commission approval jurnistaprolonge ness fiscal quarter com release tablet hydromorphone hcl anew prescription treat pany receive fda approval market precisenitinol stent ment severepain receive approval european angioguardemboli capture guidewire treat mutual recognition procedure carotid artery disease addition thecompany receive ce mark major medical device diagnostic franchise sale change dollar million vs vs depuy cordis ethicon endosurgery ethicon lifescan vision care orthoclinical diagnostic total prior year amounts restate conform current presentation management discussion analysis result operation financial condition approval europefor cypher selectsirolimuselute medical device diagnostic segment stent usein treatment severe arterial disease leg achieve sale billion represent increase april july cordis cardiology division prior year operational growth posi cordis corporation receive warning letter fda tive impact currency sale increase good manufacturing practice regulation good international sale increase clinical practice regulation response warn letter operation currency cordis improvement quality system provide periodic update fda theclinical warning analysis consolidate earning letter issue resolve fdas satisfaction provision fortaxe income respect thequality system warning letter addition improvement update cordis juarez mexico stent sup consolidated earning provision fortaxe income plier location inspect acceptable result thefda increase billion billion earn inspect miami site global quality system includ theincrease billion ing design control system august acceptable percent sale consolidate earning result cordis receive observation fda provision fortaxes income inspection thefda inspection complete cordis llc improvement change percent insan german puerto rico cordis laboratory operation sale improvement warren new jersey january completingall section follow highlight schedule follow inspection cordis process significant component change consolidated earning evaluating review overall result inspection provision taxis income fda cost product sell sell marketing andadministra theethicon endosurgery franchise achieve sale tive expensescost product sell sell marketingand billion increase major administrative expense percent sale asfollow contributor growth continue beendocutter sale include product usedin perform bariatric procedure sale thetreatment obesity important focus area thefran cost product sell chise strong result achieve success percent point increasedecrease harmonic scalpel ultrasonic cutting coagulate prior year surgical device receive approval january sell marketing administrative expand indication include plastic surgery expense stronggrowth advanced sterilization product percent point increasedecrease theethicon franchise sale grew reach prior year billion result solid growth mesh women health urology product sale increase percent sale costof gynecareproduct anddermabondhad strong result product sell unfavorable product mix higher continue growth suture sale manufacturing cost pharmaceutical consumer seg thelifescan franchise achieve billion salesin ment decrease percent sale sell mar increase animas corporation kete administrative expense result acquire fiscal quarter provide lifescan leverage selling expense reduction advertising platform entry insulin pump segment promotional spending company continuedto diabete market key contributor growth strong focus controllingexpense performance achieve onetouchultra decrease percent sale cost product line international market ofproduct sell low manufacturing cost pri sale thevision care franchise reach billion marily relate cyphersirolimuselutingstent growth rate prior year growth asongoingcostcontainmentactivity organization lead global success acuvueoasysbrand contact partially offset negative impact pharmaceutical product lense hydraclearplus acuvueadvance mix decrease percent sale sell astigmatism international success day marketing administrative expense cost acuvuemoistand acuvuedefine containment initiative pharmaceutical segmentpartially theorthoclinical diagnostic franchise achieve bil offset increase investment spend medical lion sale increase growth device diagnostic segment achieve clinical laboratory immunohematology sale decrease percent sale cost international market ofproduct sell favorable mix cost themedical device diagnostic segment achieve improvement initiative decrease sale billion represent increase cent sale sell marketing administrative expense prior year operational growth posi company focus managingexpense tive impact currency sale increase partially offset increase investment spending international sale increase oper number business focus drive future growth ation currency johnson johnson annual reportresearch developmentresearch development activi molecule account million tax iprd tie represent significant company business charge wasinclude operate profit pharmaceuti theseexpenditure relate development new product cal segment closure medical corporation company expert improvement exist product technical support product ise intellectual property biosurgical market account compliance governmental regulation theprotection million tax iprd charge wasinclude consumer patient worldwide cost research activi operating profit medical device diagnosticsseg tie exclude inprocess research development charge ment peninsula pharmaceuticals inc abiopharmaceutical com follow pany focus developingand commercialize antibiotic treat lifethreatene infectionsaccounted million tax dollar million iprd charge wasinclude operate profit research development expense pharmaceutical segment million tax iprd charge percent increase prior year relate scott lab inc refer wasinclude oper percent sale ate profit medical device diagnosticssegment company record iprd charge research development expense percent sale million tax result acquisition commer pharmaceutical segment cial rightsto certain patent knowhow field combinedresearch development sedation analgesia scott lab inc charge expense percent sale theconsumer andmedical include operating profitof medical device device diagnostic segment diagnostic segment respectively research development activity accelerate income expense netother income expense net pharmaceutical segment increase billion include gain loss relate sale writedown thecompound annual growth rate approximately ofcertain investment equity security hold johnson thefiveyear period johnson development corporation gain loss dis theincrease investment research developmentin posal property plant equipment currency gain loss segment demonstrate company focus knowledge minority interest litigation settlement liabilitie royalty base product andreflect significant number project income change income expense net inlate stage development increase income million income expense net include gain inprocess research developmentin company associate guidant acquisition agreement termination record inprocess research developmentiprd charge fee associate expense million income million taxrelated acquisition expense net include royalty incomepartially offset consumerhealthcare business pfizer inc vascular control expense associate record additional product lia systems inc ensure medical inc colbar lifescience ltd hand bility reserve theintegration cost associate innovationsllc future medical system sa consumer acquisition pfizer consumer healthcare healthcare business pfizer inc account million income expense net include royalty taxofthe iprd chargesand include operate incomepartially offset expense item profit consumersegment iprd chargesforall individually significant follow acquisition include operate profit income expense net include medical device diagnostic segment vascular controlsys expense item individually significant tem inc privately hold company focus develop med partially offset royalty income ical devicesto treat fibroid controlbleede obstetric gynecologic application account million tax operating profit segment iprd chargesensure medical inca privately hold com operating profit segment business follow pany develop devicesforpostcatheterization closure femoral artery account million taxofthe iprd percent chargescolbar lifescience ltd privately hold company special segment sale dollar million ize reconstructive medicine tissue engineering account consumer million taxofthe iprd charge hand innovation pharmaceutical llc privately hold manufacturer fracture fixation product upper extremity account million taxofthe med devices diag iprd chargesfuture medical systems sa privately hold segment total company primarily develop manufacturesand market incomeexpense arthroscopic fluid management system account million allocate taxofthe iprd charge segment company record iprdcharge million earning tax relate acquisition oftransform pharmaceutical provision taxis inc closure medical corporation peninsula pharmaceuticals inc income international commercial right certain patent amount allocate segment include interest incomeexpense minority knowhow fieldof sedation analgesia scott lab inc interest general corporate incomeexpense transform pharmaceuticals inc company specialize dis covery superior formulation novelcrystalline form drug management discussion analysis result operation financial condition operatingprofit interest income increase million bysegment primarily high rate interest high average inbillion dollar cash balance cash balance include current marketable security billion end average consumer billionascompare billion average cash balance pharmaceutical medical device interest expense decrease compare anddiagnostic decrease average debt balance billion billion provision taxis incometheworldwide effective income tax rate tax rate benefit reversal tax allowance million associate tibotec business partially consumer segmentconsumer segment operating profit offset guidant acquisition agreement termination fee decrease percent sale record rate theeffective taxrate include operate profitdeclinedto result million abenefit million reversal tax liability pre iprd expense expense associate pfizer viously record fiscal fourth quarter relate consumer healthcare integration record con technical correction americanjobs creation act sumer segment operating profit increase prior year percent sale operating profit increase slightly despite increase investment liquidity capital resource spending advertising research development cash flow pharmaceutical segmentin pharmaceutical segment cash flow fromoperations billion increase operating profit increase percent sale billion theincrease cash generate increase increase result million operation result net incomeincrease billion iprd record partially offset increase net noncash impact iprd charge themajor change research development spending low gross margin asset liabilitie billion increase account pharmaceutical segment operating profit payable accrue liability partially offset billion decrease percent sale decline increase defer taxis billion increase change primarily increase current noncurrent asset investment research development spending net cash investing activity increase bil theimpact million iprd expense lion primarily billion increase acquisi tion activity occur late fiscal fourth medical device diagnostic segmentin oper quarter detail discussion merger acquisi ate profit themedical device diagnostic segment tion note billion net decrease increase percent sale increase sale ofinvestment capital expenditure billion theprimary driver improve operate profit billion billion respectively guidant acquisition agreement termination fee associate net cash financing activity increase bil expense million record par lion billion common tially offset increase iprd charge addition advertis stockrepurchase program publicly announce ingandpromotional expense leverage offset march complete earlyin fiscal fourth quarter increase research development spending partially offset billion net proceed medical device diagnostic segment short term debt operating profit increase percent sale cash currentmarketable security billion increase increase drive atthe end compare billion end improve gross margin cost reduction program primarily acquisition consumer product mix primarily related thecyphersirolimuselute healthcare business pfizer inc december stent partially offset increase investment cash generate operation amount billion research development spending billion cash generate interest income expenseinter income increase operation billion themajor factor contribute million primarily high rate interest increase net incomeincrease billion net high average cash balance despite billion common noncash impact iprd charge billion decrease stock repurchase program increase acquisition activity inother current noncurrent asset contribute cash balance include current marketable security increase partially offset billion decrease billion end average billion account payable accrue liability additionally cash pay compare billion average cash balance ment approximately billion previously interest expense increase slightly compare accrue taxis repatriation undistribute international high average debt balance billion earning accordance american job creation act billion partially offset increase approximately billion decrease interest rate pension fundingin compare johnson johnson annual reportoper net debt billion compare net cash billion total debt represent total capitalshare p pe holders equity total debt total capital billion dollar shareholder equity share endof ial ndi r compare yearend increase rain lo theperiod end december material cash commitment johnson johnson continue beone industrial company triple credit rating summary borrowing find note longterm contractualobligation andcommitment thecompany longterm contractual obligation primarily finance market risk lease debt obligation unfunded retirement plan thecompany use financial instrument manage impact significant obligation satisfy theseobligation foreign exchange rate change cash flow accordingly company use cash operation thefollowing table thecompany enter forward foreign exchange contract summarize company contractual obligation protect value certain foreign currency asset liability aggregate maturity december note hedge future foreign currency product cost gain detail loss contract offset gain loss onthe longterm unfunded underlyingtransaction appreciation dollar operate debt retirement december market rate wouldincrease dollar million lease obligation plan total unrealized value company forward contract million conversely depreciation dollar december market rate woulddecrease theunrealize value company forward contract million scenario gain loss forward contract wouldbe offset gain loss underlie transaction wouldhave impact future total earning cash flow thecompany hedge exposure fluctuation cur amount include interest expense rency exchange rate effect certain asset liabili tie foreign currency enter currency swap contract share repurchase dividend change spread foreign interest march company announce board rate company interest rate sensitive financial instru director approve stock repurchase programauthorize ment increase decrease unrealized value company buy billion company com company swap contract approximately million monstock program complete early fiscal fourth scenario maturity gain loss swap contract quarter million share repurchase addition wouldbe offset gain loss underlie transaction thecompany annual program repurchase share wouldhave impact future cash flow use employee stock incentive plan thecompany enter financial instrument thecompany increase dividend th fortrade speculative purpose company consecutive year cash dividend pay share policy enter contract party compare dividend share equivalent credit rating thecounterpartie share thedividend distribute contract major financial institution follow significant concentration exposure counter party management believe risk loss remote quarter total unused credit available company approximate second quarter billion include billion credit commitment ofwhich billion expire september billion quarter expire october billion expire september fourth quarter include billion uncommitted line total bank worldwide expire totalborrowing end january board director declare regular cash billion billion respectively increase borrowing dividend share payable march share resultof financingthe acquisition holder record february company expect consumerhealthcare business pfizer incin december continue practice pay regular cash dividend net debt cash current marketable security management discussion analysis result operation financial condition information table progression accrue rebate return promotion reserve doubtful account critical accounting policy estimate reserve cash discount segment business theyear management discussion analysis result operation end december january financial condition base company consolidate financial statement prepare accordance consumer segment accountingprinciple generally accept theprepara tion financial statement require management balance balance estimate assumption affect amount begin payment end dollar million period accrual period report revenue expense asset liability relate disclosure actual result differ estimate thecompany believe understand accrue rebate certain key accountingpolicie estimate essential accrue return achieve insight company operating result accrue promotion financial condition thesekey accountingpolicie include rev subtotal enue recognition incometaxe legal self insurance contin reserve doubtful account gencie valuation longlive asset assumption reserve cash discount determine amount record forpension total employee benefitplan accountingfor stock option revenue recognitionthecompany recognize revenue accrue rebate product sale good ship deliver title accrue return risk loss pass customer provision certain rebate accrue promotion sale incentive trade promotion coupon product return subtotal discount customer account reduction sale reserve doubtful account thesame period relate sale record product discount grant base term reserve cash discount arrangement direct indirect market participant total market condition includingprice charge com include reserve customerrebate million december petitor rebate large medicaid rebate provi million january record contra asset sion estimate base sale term historical experience trend analysis project market condition pharmaceutical segment market servedthecompany evaluate market condition balance balance product group product primarily analysis begin payment end wholesaler party sellthrough market dollar million period accrual period research datum internally generate information sale return generally estimate record base accrue rebate onhistorical sale return information product exhibit accrue return unusual sale return pattern dating competition accrue promotion orother marketing matter specifically investigate subtotal analyze accountingfor sale return accrual reserve doubtful account sale return allowance represent reserve products reserve cash discount return expiration destruction field specific area product recall thereturns reserve base total historical return trend product market percent gross sale accrue rebate promotional programssuch product list allowance accrue return cooperative advertising arrangement record accrue promotion year incur continuingpromotional program include subtotal coupon andvolumebase sale incentive program redemption cost consumer coupon base historical reserve doubtful account redemption experience product value volumebase reserve cash discount incentive program derive estimate sale volume total incentive period record product sell include reserve customerrebate million december reasonablylikely change assumption calculate million january record contra asset accrual rebate return promotion antici include million relate previously estimate performancebase rebate pat amaterial effect financial statement allowance manage care contract company currently disclose impact change assump tion thequarterly annual file financial statement impact johnson johnson annual reportmedicaldevicesand diagnostic segment insurer recovery probable appropriate reserve receivables record estimate amount balance balance collect partyinsurer begin payment end dollar million period accrual period longlivedand intangible assetsthecompany assess change economic condition andmake assumption regard accrue rebate ing estimate future cash flow evaluate value accrue return company property plant equipment goodwill intangi accrue promotion ble asset assumption estimate change subtotal time itmay necessary thecompany reserve doubtful account record impairment charge reserve cash discount employee benefit plansthecompany sponsor retire total ment pension plan include define benefit define con tribution termination indemnity plan cover accrue rebate employee worldwide plan base assumption discount rate expect return plan asset expect accrue return salary increase health care cost trend rate note accrue promotion detail rate effect rate change subtotal company result operation thecompany reserve doubtful account adopt sfas employer account define pension reserve cash discount postretirement plan amendment fasb state total ment rthis statement require recognition fundedstatus benefit plan state include reserve customerrebate million december million january record contra asset ment financial position change fund status theyear change occur recognize company earn service revenue copromotion cer comprehensive incomeoci net tax tain product year present service revenue stock optionsdure fiscal quarter com total revenue include salestocustomer pany adopt sfas rshare base paymentthecom income taxesincometaxes record base amount pany apply modify retrospective transition method refundable payable thecurrent year include result implement sfas r previously report financial state difference gaap accountingandus tax ment restate accordance provision report record defer tax assetsor liability thecom sfas r note information pany estimate defer tax assetsand liability base cur stock option rent tax regulation rate change tax law rate affect record defer tax asset liability future newaccounting standard management believe change estimate wouldnot december financial accountingstandards board result material effecton thecompany result operation fasb issue sfas rshare base payment state cash flow financial position ment establish standard accountingfor transaction company repatriate billion undistrib entity exchange equity instrument good uted international earning accordance american service focus primarily accountingfor transaction job creation act ajca record tax charge entity obtain employee service sharebase pay million thefiscal fourth quarter ment transaction employee stock option fiscal second quarter company record taxben restrict stock unit thestatement require measurement efitof million reversal tax liability previ cost employee service receive exchange ously record fiscal fourth quarter award equity instrument employee stock option associate technical correction ajca restrict stock unit fair value grant date atdecember january cumula cost recognize period tive undistribute international earning approx employee require provide service exchange imately billion billion respectively thecompany award requisite service period thecompany adopt intend continue reinv undistributed international statement fiscal quarter apply modi earning expand international operation fie retrospective transition method previously report finan tax expense record cover undistribute por cial statement restate reflect adoption tion intend forrepatriation sfas r legaland selfinsurance contingenciesthecompany record accrual contingency include legal proceeding product liability case arise normal course business theaccrual base management judgment probability loss opinion legal counsel applicable actuarially determined estimate additionally company record insurance receivable amount party management discussion analysis result operation financial condition thecompany implement sfas inventory cost economic market factor amendment arb thefiscal quarter johnson johnson aware product environ adoption statement amaterial effect ment whereformore decade policymaker consumer companys result operation cash flow financial position business express concern abouttherise cost health june fasb issue fasb interpretation fin carein response concern johnson johnson long accounting uncertainty income taxis interpretation stand policy pricing product responsibly forthe period fasb statement interpretation prescribe recog united statesthe weight average compound annual nition threshold measurement attribute financial growth rate ofjohnson johnson net price increase forhealth care statement recognition measurement tax position take product prescription overthecounter drugshospitalandpro expected take tax return theinterpretation fessional product consumerpriceindex cpi provide guidance derecognition classification inflation rate moderate part matter fin effective thefiscal year worldduring continue effect worldwide company adopt accordingly thecompany assess economy consequently way company operate impact adoption fin currently inthe face increase cost company strive maintain believe adoption material effect result profit margin cost reduction program productivity operation cash flow financial position improvement periodic price increase thecompany september fasb issue statement financial facesvarious worldwide health care change result accounting standard fair value measurementsthis inprice pressure include health care costcontainment statement define fair value establishe framework measur government legislation relate sale promotion e fair valuein generally accept accounting principle andreimbursement expand disclosure fair valuemeasurement state thecompany operate environment ment effective fiscal quarter com becomeincreasingly hostileto intellectual property right pany adopt thestatement time company believe generic drugfirm file abbreviate new drug applica adoption sfas material effect tion seek market generic form company result operation cash flow financial position key pharmaceutical product prior expiration applicable september fasb issue statement financial patent cover product event company accountingstandard employer account define successful defend patent claim challenge abbrevi pensionand postretirement plan amendment fasb ate new drug application filing generic firm statement rthis statement require introduce generic version product issue result recognition fundedstatus benefit plan state potential substantial market share revenue loss ment financial position require recognition product information thediscussion liti component comprehensive incomeoci net tax gation filer abbreviate newdrug application gain loss prior service cost credit arise note period butare recognize component net periodic benefit cost pursuant statement legal proceeding statement new provision measurement thecompany involve numerous product liability case date certain disclosure requirement thestatement united states concern adverse reaction effective fiscal year end company adopt drug medical device thedamage claim substan statement time tial company confident adequacy september sec issue staff accounting thewarning instruction use accompany bulletin sab express staff view product feasible predictthe ultimate outcomeof process quantify financial statement misstatement litigation company believe liability thebulletin effective fiscal year end theimple result case willbe substantially cover mentation bulletin impact company exist amount accrue company balance sheet result operation cash flow financial position underitsselfinsurance program party product thefollowing accountingpronouncement liability insurance effective nothave material impact thecompany involve anumber patent trade company result operation cash flow financial position mark lawsuit incidental business theultimate fin accounting conditional asset retirement legal financial liability company respect obligation interpretation fasb statement claim lawsuit proceeding refer sfas exchange nonmonetary assets amendment estimate certainty company opin apb ion base examination matter experience thefollowing accountingpronouncement effective todate discussion counsel theultimate outcome material impact company result oflegal proceeding net liability accrue operation cash flow financial position company balance sheet expect material eitf issue investor apply equity adverse effect company financial position method accounting investment common stock theresolution reporting period eitf issue accounting preexisting relationship matter couldhave significantimpact company result party business combination operation cash flow period note information legal proceeding johnson johnson annual reportcommon stock market price thecompany common stock list new york stock exchange symbol jnj thecomposite market price range johnson johnson common stock high low high low quarter second quarter quarter fourth quarter yearend close cautionary factor affect future result annual report contain forwardlooke statement forwardlooke statement relate strictly historical orcurrent fact anticipate result base management plan subject uncertainty forwardlooke state ment identify use word like plan expect anticipate estimate word similar meaning conjunction amongotherthing discus sion future operation financial performance company strategyfor growth product development regulatory approval market position expenditure forwardlooke statement base current expecta tion future event thecompany guarantee anyforwardlooking statement accurate company believe itha reasonable expectation assumption investor realize underlying assumption prove inaccurate unknown risk uncer taintie materialize actual result couldvary materially company expectation projection investor caution place undue reliance forwardlooke statement thecompany undertake update wardlooking statement result new information future event development risk uncertainty include general industry condition competition economic condition interest rate currency exchange rate fluctuation technological advance new product andpatent attain competitor challenge inherent new product development include obtain regu latory approval challenge patent foreign health care reform andgovernmental law regulation trend health care costcontainment increase scrutiny health care industry government agency product efficacy safety concern result product recall regulatory action thecompany report theyear end december include exhibit discussion additional factor couldcause actual result differ expectation thecompany note factor permit bythe private security litigation reform act management discussion analysis result operation financial condition consolidated balance sheet johnson johnson subsidiaries december january dollar million share share datum note asset current asset cash cash equivalent note marketable security note account receivable trade allowance doubtful account inventory note defer taxis incomenote prepay expense receivables total current asset marketable security noncurrent note property plant equipment net note intangible asset net note goodwill net note defer taxis incomenote asset note total asset liability shareholder equity current liability loan andnote payable note account payable accrue liability accrue rebate return promotions accrue salary wage commission accrue taxis income total current liability longterm debt note defer taxis incomenote employee relate obligation note liability total liability shareholder equity prefer stockwithout par value authorize unissued share common stockpar value share note authorize share issue share accumulate comprehensive incomenote retain earning common stock hold treasury cost note share share total shareholder equity total liability shareholder equity note consolidated financial statement johnson johnson annual reportconsolidate statement earnings johnson johnson subsidiarie dollar million share figure note sale customer cost product sell gross profit selling marketing administrative expense research expense purchase inprocess research development note interest income interest expense net portion capitalize note income expense net earning provision taxis income provision taxis incomenote net earning basic net earningspershare note diluted net earning share note sseeee nnootteess ttoo ccoonnssoolliiddaatteedd ffiinnaanncciiaall ssttaatteemmeennttss consolidated financial statement consolidate statement equity johnson johnson subsidiary note receivable accumulate employee treasury comprehensive retain stock ownership comprehensive common stock stock dollar million note total income earning plan esop income issue balance december net earning cash dividendspaid employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize gain security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividendspaid employee stock compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan gain derivative hedge reclassification adjustment total comprehensive income note receivable esop balance january net earning cash dividendspaid employee compensation stock option plan conversion subordinate debenture repurchase common stock comprehensive income net tax currency translation adjustment unrealize loss security employee benefit plan loss derivative hedges reclassification adjustment total comprehensive income balance december note consolidated financial statement johnson johnson annual reportconsolidate statement cash flow johnson johnson subsidiaries dollar million note cash flow operating activity net earning adjustment reconcilenet earning cash flow depreciation andamortization property intangible stock basedcompensation purchase inprocess research development defer tax provision account receivable allowance change asset liability net effect fromacquisition increase account receivable increasedecrease inventory increasedecrease account payable accrue liability increasedecrease current noncurrent asset increase current noncurrent liability net cash flow operating activity cash flow invest activity addition property plant equipment proceed disposal asset acquisition net cash acquire note purchase ofinvestment sale investment primarily intangible net cash investing activity cash flow financingactivitie dividend shareholder repurchase common stock proceed shortterm debt retirement shortterm debt proceed longterm debt retirement longterm debt proceed exercise stock optionsexcess tax benefit net cash financing activity effect exchange rate change cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year note cash cash equivalent endof year note supplemental cash flow datum cash pay year interest incometaxe supplemental schedule noncash investing financing activity treasury stock issue employee compensation stock option plan net cash proceed conversion debt acquisition fair value asset acquire fair value liability assume net cash pay acquisition sseeee nnootteess ttoo ccoonnssoolliiddaatteedd ffiinnaanncciiaall ssttaatteemmeennttss consolidated financial statement note consolidated financial statement summary significant accounting policy apply modify retrospective transition method principle consolidation previously report financial statement restate theconsolidated financial statement include account reflect adoption sfas r note johnson johnson subsidiarie thecompany inter company implement sfas inventory cost company account transaction eliminate anamendmentof arb fiscal quarter adoption statement material effect description company business segment company result operation cash flow financial position thecompany approximately employee worldwide june fasb issue fasb interpretation fin engage research development manufacture sale accounting uncertainty income taxis interpretation abroad range product thehealth care field thecom fasb statement interpretation prescribe recog pany conduct business virtually country world nition threshold measurement attribute financial itsprimary focus product relate human health statement recognition measurement tax position take andwellbeing expect take tax return theinterpretation thecompany organize business segment provide guidance derecognition classification consumer pharmaceutical medical device diagnos matter fin effective thefiscal year tic theconsumer segment manufacture market broad company adopt accordingly thecompany assess range product usedin baby kid care skin care impact adoption fin currently believe oralcare woundcare women health care field adoption material effect result nutritional overthecounter pharmaceutical product operation cash flow financial position theseproduct market principally general public september fasb issue statement financial sell wholesaler directly independentand accounting standard fair value measurementsthis chain retail outlet world thepharmaceutical statement define fair value establishe framework measur segment include product thefollowe therapeutic area e fair valuein generally accept accounting principle antifungal antiinfective cardiovascular contraceptive derma expand disclosure fair valuemeasurement state tology gastrointestinal hematology immunology neurology ment effective fiscal quarter com oncology pain management psychotropic central nervous sys pany adopt thestatement time company believe tem urology virology area theseproduct distribute adoption sfas material effect directly retailer wholesaler health care professional result operation cash flow financial position prescription use general public themedical device september fasb issue statement financial diagnostic segment include broad range ofproduct accountingstandard employer account define principally professional field byphysicians nurse thera pensionand postretirement plan amendment fasb pist hospital diagnostic laboratory clinic theseprod statement rthis statement require uct includecordis circulatory disease management product recognition fundedstatus benefit plan state depuy orthopaedic joint reconstruction andspinal care prod ment financial position require recognition uct ethicon woundcare women health product component comprehensive incomeoci net tax ethicon endosurgerys minimally invasive surgical product gain loss prior service cost credit arise lifescans blood glucose monitor andinsulin delivery period butare recognize component net product orthoclinical diagnostic professional diagnostic periodic benefit cost pursuant statement product andvision care disposable contact lense statement new provision measurement date certain disclosure requirement thestatement newaccounte pronouncement effective fiscal year end company adopt december fasb issue sfas rshare statement time note base paymentthis statement establish standard september sec issue staff accounting accountingfor transaction entity exchange bulletin sab express staff view equity instrument good andservice focuses primarily process quantify financial statement misstatement accountingfor transaction entity obtain thebulletin effective fiscal year end theimple employee service sharebase payment transaction mentation bulletin impact company employee stock option restrict stock unit thestate result operation cash flow financial position ment require measurement cost employee service thefollowing accountingpronouncement receive exchange award equity instrument effective nothave material impact employee stock option restrict stock unit fair value company result operation cash flow financial position grant date cost recognize period fin accounting conditional asset retirement employee require provide service obligation interpretation fasb statement exchange award requisite service period thecom sfas exchange nonmonetary assets amendment pany adopt statement fiscal quarter apb johnson johnson annual reportthe follow accounting pronouncement effective product group product primarily analysis material impact company wholesaler party sellthrough market result operation cash flow financial position research datum internally generate information eitf issue investor apply equity sale return generally estimate record base method accounting investment common stock historicalsale return information product exhibit eitf issue accounting preexisting relationship unusual sale returnpattern date competition party business combination marketing matter specifically investigate analyze aspart ofthe accounting forsale returnaccrual sale return cash equivalent allowancesrepresent reserve product bereturne thecompany consider security maturity expiration destruction field specific area prod month purchase becashequivalent uct recall return reserve base historicalreturn trend product market percent togross sale investment promotional programssuch product list allowance shortterm marketable security carry cost cooperative advertising arrangement record approximate fair value investment classify availablefor year incur continuingpromotional program include sale carry estimate fair value unrealize gain coupon andvolumebase sale incentive program loss record component accumulate compre redemption cost consumer coupon base historical hensive income longterm debt security company redemption experience product value volumebase ability intent hold maturity carry amortize incentive program base estimate sale volume cost approximate fair value management determine incentive period record product sell appropriate classification investment debt equity company earn service revenue copromotion certain security time purchase reevaluate determi product andinclude sale tocustomer nation balance sheet date thecompany periodically review investment equity security impairment shipping handle adjust investment fair value decline shipping handling cost incur million mil market value deem otherthan temporary lion million respectively include sell marketing administrative expense property plant equipment depreciation revenue receive shipping andhandle property plant equipment state cost sale customer period present companyutilize straightline methodof depreciation overthe estimate useful life asset inventory inventory state low cost market determine building building equipment year firstin firstout method land leasehold improvement year machinery equipment year goodwill intangible asset effective beginningof fiscal year accordance thecompany capitalize certain computer software sfas company discontinuedthe amortization relat development cost include machinery andequipment ing exist goodwill indefinite live intangible asset incur connection develop orobtainingcomputer nonamortizable sfas require thatgoodwill software internal use capitalize software cost amor nonamortizable intangible asset assess annually tize estimate useful life ofthe software impairment thecompany complete annual impairment generally range year test thefiscal fourth quarter impairment thecompany review longlive asset assess recover determined future impairment test beperforme annually ability undiscounted cash flow necessary charge thefiscal fourth quarter soon trigger eventoccur impairment longlive asset record theamount intangible asset finite useful life continue bywhich present value future cash flow amortize useful life review impair carrying value asset ment warrant economic condition note detail intangible asset revenue recognition thecompany recognize revenue product sale good ship deliver title riskof loss pass financial instrument thecompany follow provision sfas accounting customer provision certain rebate sale incentive derivative instrument hedge activitiesas amend trade promotion product return discount customer sfasno require derivative instrument record account reduction sale inthe period balance sheet fair value change fair value relate sale record derivative record period current earning product discount grant base term comprehensive income depend thederivative arrangement direct indirect market participant designate hedge transaction ifso type market condition includingprice charge com hedge transaction petitor rebate large medicaid rebate provi sion estimate base sale term historical experience trend analysis project market condition market servedthecompany evaluate market condition note consolidated financial statement company use forward exchange contract manage advertising exposure variability cash flow primarily relate cost associate advertising expense year incur theforeign exchange rate change future intercompany prod include sell marketing administrative uct party purchase raw material denominate expense advertising expense worldwide arecomprise foreign currency company use currency swap man television radio print medium internetadvertise bil age currency risk primarily relate borrowing lion billion billion type derivative designate cash flow hedge addition ally thecompany use forward exchange contract tooffset income taxis exposure certain foreign currency asset liability thecompany intend continue reinv undistributed forward exchange contract designate hedge international earning expand international operation change fair value derivative tax expense record cover recognize earningsthereby offset current earning undistribute portion intend forrepatriation atdecember effect relate foreign currency asset andliabilitie andjanuary cumulative undis designation cash flow hedge entrance tribute international earning approximately billion date derivative contractat inception derivative billion respectively expect highly effective change fair valueof defer incometaxe recognize tax consequence derivative designate cash flow hedgeand highly oftemporary difference apply enact statutory taxrate effective record accumulate othercomprehensive applicable future year differences thefinancial income underlie transactionaffect earning report tax basis exist asset andliabilitie reclassify earning account hedge transaction fair valueof derivative instrument ie forward net earning share foreign exchange contract currency swap aggregation basic earning share compute divide net earning currency future cash flow discount present valueat available common shareholder weight average prevailingmarket interest rate subsequently convert number common share outstanding theperiod dilute theus dollar current spot foreign exchange rate earning share reflect potential dilution thatcouldoccur ongoing basis company assess security exercise convert common stock derivative continue behighly effective offset change treasury stock method thecashflow hedge item derivative isno long expect behighly effective hedge accountingisdis use estimate continue hedge ineffectiveness include current preparation consolidate financial statement period earning insignificant conformity accounting principle generally accept company document relationship hedge require management estimate assumption item derivative overall risk management strategy affect amount report estimate include reason undertakinghedge transaction enter accounting sale discount rebate allowance incen derivative objective strategy minimize tive product liability income taxis depreciation amortization foreign currency exposure impact company financial employee benefit contingency intangible asset liabil performance protect company cash flow adverse ity valuation instance determine annual pension movement foreign exchange rate ensure appropriate postemployment benefit cost company estimate rate ness financial instrumentsand manage enterprise risk return plan assetsand cost future health care bene associate financialinstitution fit actual result differ estimate product liability annualclose date accrual product liability claim record undis thecompany follow concept fiscal year end onthe count basis itis probable liability incur sunday nearestto theend month december normally liability reasonably estimate base fiscal year consist week orsix year exist informationthe accrual adjust periodically fiscal year consist week case additional information available resultof cost availability factor effective november company inventory cease purchase party product liability insurance base end inventory comprise theavailability prior coverage receivables insurance recover ies relate product liability claim record onanundi dollar million count basis itis probable thata recovery realize raw material supply good process research development finish good research development expense expense incurred upfront andmilestone payment party con nection research development collaboration expense incur point regulatory approval pay ment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize suchpayment include intangible net accumulate amortization johnson johnson annual report property plant equipment borrowing end property plant equipment thecomponent longterm debt follow costand accumulate depreciation effective effective dollar million dollar million rate rate land land improvement zero coupon convertible subordinate building build equipment debenture machinery equipment debenture construction progress debenture note accumulate depreciation debenture note industrial revenue bond thecompany capitalize interest expense cost construction facility equipment interest expense capi talize million million current portion million respectively depreciation expense include amortization capital ize interest billion bil weight average effective rate lion billion respectively retirement disposal property plant equip company access substantialsource fund ment cost relate accumulate depreciation numerous bank worldwide total unused creditavailable oramortization eliminate asset accumulate company approximate billion include billion depreciation account respectively difference creditcommitment billion expire september net asset value proceed record inearning billion expire october billion expire september include billion uncommitted line bank worldwide expire rental expense lease commitment interestcharge borrowing credit rental space vehicle manufacture equipment line agreement base bid provide bank officeand datum processing equipment operating lease prime rate london interbank offer rate libor plus approximately million million applicable margin commitment fee agreementare million material theapproximate minimum rental payment require thecompany file shelf registration security operating lease initial remain noncancelable exchange commission sec effective novem lease term excess year december ber enable company issue bil lion debt security warrant purchase debt security dollar million total debt issue remain available december july alza complete private offering commitment capitallease significant zero coupon convertible subordinated debenture issue price principal employee relate obligation maturity december outstanding debenture end employee relate obligation total principal maturity million yield maturity annum compute semiannual dollar million bond equivalent basis periodic interest payment pension benefit term debenture holder entitledto postretirement benefit convert debenture approximately million share postemployment benefits johnson johnson stock price share defer compensation approximately million share issue decem ber voluntary conversion note holder current benefit payable option holder debenture repurchase company july purchase price employee relate obligation equal issue price plus accrete original issue discount purchase date thecompany option elect prepay employee relate obligation million deliver johnson johnson common stock cash million respectively include combination stock andcash eventof repurchase ofthe asset consolidate balance sheet prepay debenture thecompany option redeem employee relate obligation decrease significantly debenture july issue implementation sfas note consolidated financial statement price plus accrete original issue discount december goodwillas december january allo january fair value base quote market cat segment business follow value debenture million med dev million respectively dollar million consumer pharm diag total shortterm borrowing current portion long term goodwill debtamounte billion end january billion raise commercial paper program acquisition theremainder represent principally local borrowing translationother international subsidiary goodwill aggregate maturity longterm obligation commence january acquisition translationother dollar million goodwill december certain business relationship theweighte average amortization period patent member companys board director chief trademark intangible asset year year executive officer major bank bank provide ser respectively theamortization expense amortizable intangible vice thecompany include provide line credit asset thefiscal year end december january payment significant january million million company bank million taxrespectively certain patent intan gible write fair value fiscal year result charge include amortiza intangible asset goodwill tion expense theestimate amortization expense thefive end gross net amount succeed year approximate million taxp year intangible asset goodwill substantially amortization expense include cost dollar million product sell trademark nonamortizablegross accumulate amortization income taxis trademark nonamortizablenet theprovision taxis incomeconsist patent trademarksgross accumulate amortization dollar million currently payable patent trademarksnet taxis intangiblesgross international taxis accumulate amortization intangiblesnet defer subtotal intangible assetsgross taxis accumulate amortization international taxis subtotal intangible assetsnet goodwillgros accumulate amortization goodwillnet total intangible asset goodwillgross accumulate amortization total intangible asset goodwillnet johnson johnson annual reporta comparison incometax expense federal statutory rate international currency translation company effective tax fortranslation subsidiary operate nonus dollar curren rate follow cie company determine thatthe local currency international subsidiary functional currency dollar million highly inflationary economy define compound cumulative rate inflation international past year substantial portion earning taxis cash flow local currency income consolidate international subsidiary balance sheet tax rate currencyeffect record component accumulate statutory comprehensive income equity account include puerto rico result translate balance sheet asset liability ireland operation current exchange rate locate highly infla research orphan drug taxcredit tionary economy reflect operating result state local analysis change international subsidiary foreign currency translation adjustment include note exclude ireland net currency transaction translation gain loss repatriation include income expense net loss international earning million million million iprd respectively effective tax rate common stockstock option plan stockcompensation agreement company hadsubsidiarie operate puerto rico stock option tax incentive grant theus possession tax credit december company stockbase com expire apply certain operation puerto pensation plan theshare outstanding contract rico addition company subsidiary manufacture company stock option plan ireland incentive tax rate increase tax longterm incentive plan stock compensation plan rate mainlydue reversal atax liability million nonemployee director plan centocor inno report tax provision result technical vasive device alza inverness scio stock option plan correction american job creationact option restrict stock grant partiallyoffset benefit report forthe reversal tax plan exceptthe longterm incentive plan allowance million associate tibotec business thecompensation cost record sfas r temporary difference carry forward charge incomefor plan asfollow million million million thetotal incometax benefit recognize income defer tax defer tax statement share base compensation cost million dollar million asset liability asset liability million million employee relate obligation share base compensation cost capitalize inventory insignificant period stock base compensation stock option expire year date grant depreciation vest service period range month nondeductible intangible year option grant currentmarket price international rd capitalize dateof grant longterm incentive plan tax company issue million share common stock reserve liabilitie share available future grant longterm income report tax purpose incentive plan million endof miscellaneous international thecompany settle employee stock option exercise capitalize intangible treasury share treasury share replenish miscellaneous year thenumber share settle employee stock total deferred income taxis option exercise thedifference net defer tax incomeper thebalance sheet net defer tax include taxis incomeon balance sheet note consolidated financial statement fair value option award estimate date summary option activity plan december grant blackschole option valuation model use january january change assumption note follow table start year end date present expect volatility represent blend rate year daily weight aggregate historicalaverage volatility rate week average imply outstanding average intrinsic volatility rate base atthemoney trade johnson johnson share thousand share exercise price value option life year prior expect volatility share december wasbase year weekly historical volatility rate historical option grant datum isuse determine expect life option option exercise riskfree rate base treasury yield curve effect option canceledforfeite atthe time grant share january theaverage fair value option grant thefair value option grant estimate base weighted average assumption option exercise option canceledforfeite share january riskfree rate expect volatility option grant expect life yrs yrs yrs option exercise dividendyield option canceledforfeite share december thetotal intrinsic value option exercise million million million respec tively thetotal unrecognized compensation cost million december million january million january theweighte average period cost berecognized year year year thefollowing table summarize stock option outstanding exercisable december share thousandsoutstande exercisable average average exercise average exercise exercise price range option life price option price average contractual life remain year stock option exercisable january january summary stock activity plan average price average december life year option average price outstanding average life year respectively share thousand share share january restrict stock unit stock grant company grant restrict stockunit aveste periodof stock issue year company settle employee stockissuance stock canceledforfeite treasury sharestreasury sharesare replenish year forthe number ofsharesuse foremployee stockissuance share december average fair value restrict stock unit grant fair marketvalue date ofgrant fair value restrict stock unit discount fordividend pay restrict stock unit vest periodthe fair value sharesissue million johnson johnson annual report segment businessand geographic area sale customer dollar millions consumerunite states international total pharmaceuticalunite state international total medical device diagnosticsunite state international total worldwide total operating profit identifiable asset dollar million consumer pharmaceutical medical device diagnostic segment total incomeexpense allocate segment general corporate worldwide total addition property depreciation plant equipment amortization dollar million consumer pharmaceutical medical device diagnostic segment total general corporate worldwide total sale customer longlive asset dollar millions united states europe western hemisphere exclude asiapacific africa segment total general corporate non longlived asset worldwide total note description segment company operate export sale intersegment sale significant thecompany customer represent ormore total revenue sale distributor account total revenue amount allocate segment include interest incomeexpense minority interest general corporate incomeexpense general corporate include cash marketable security include million million inprocess research development iprd consumerand medical device diagnostic segment respectively medical device diagnostic segment include guidant acquisition agreement termination fee associate expense million include million million iprd pharmaceutical medical device diagnostic segmentsrespectively include million iprd medical device diagnostic segment longlive assetsinclude property plant equipment net respectively intangible asset net respectively note consolidated financial statement accumulate comprehensive income tax effecton unrealize gainslosses equity component comprehensive incomeloss consist security balance expense million million follow million respectively tax effectrelate employee benefit plan million million total thetax effecton gainslosses derivativesand unrealized gain accumulate foreign gain loss hedge loss million million currency loss employee derivative comprehensive benefit million note foradditional dollar million translation security benefit plan hedge incomeloss information relate derivative hedge dec thecurrency translation adjustment currently change adjusted incometaxe relate permanent net change investment international subsidiary hedge transaction net reclasse net earning pension benefit plan net change thecompany sponsor retirement pension plansincludingdefine benefit define contribution jan termination indemnity plan cover employee change worldwide thecompany provide postretirement bene net change fitsprimarily health care insurance retire employee hedge transaction theirdependent net reclasse international employee cover government net earning sponsor program thedirect cost company net change isnotsignificant jan retirement plan benefit primarily base change employee compensation year net change retirement number year service interna hedging transaction tional subsidiary plan fund deposit net reclasse trustee annuity purchase group contract net earning reserve provide net change thecompany fund retiree health care benefit dec advance right modify plan future thecompany use date consolidate financial total comprehensive incomefor include reclassifi statement december january respec cation adjustment gain million realize saleof tively measurement date international equity security associate tax expense million retirement benefitplans total comprehensive incomefor include reclassifi september fasb issue statement financial cation adjustment gain million realize saleof accounting standard employer account define equity security associate tax expense million benefit pension postretirement plan amendment total comprehensive incomefor include reclassifi fasb statement rwhich require cation adjustment gain million realize saleof employer fully recognize overfunde underfunde sta equity security associated tax expense million tus pension postretirement benefit plan asset liability financial statement addition com pany require recognize component compre hensive income loss actuarial gain loss prior service cost credit arise duringtheperiod immediately recognize component net periodic benefit cost theincremental effect apply sfas bil lion reduction shareholder equity netof defer taxis johnson johnson annual reportnet periodicbenefit cost thecompany define benefit retirement plan benefit plan includedthe follow component retirement plan benefit plan dollar million service cost interest cost expect return plan asset amortization prior service cost amortization net transition asset recognize actuarial loss curtailment settlement net periodic benefit cost thenet periodic benefit cost attributable retirement plan amount expect berecognized net periodic cost million million mil come year thecompany define benefit retirement lion plan postretirement plan dollar million amortization net actuarial loss amortization prior service cost amortization net transition obligation theweightedaverage assumption follow table represent rate develop actuarial present value pro jecte benefit obligation theyear list net periodic benefit cost thefollowing year retirement plan benefit plan dollar million benefit plan discount rate expect longterm rate return plan asset rate increase compensation level international benefit plan discount rate expect longterm rate return plan asset rate increase compensation level company discount rate determine consideringcurrent thefollowing table display assume health care cost yield curve represent high quality longterm fix income instru trend rate individual ment result discount rate consistentwith duration health care plan plan liability health care cost trend rate assume year theexpected longterm rate return plan asset rate cost trend rate assume assumption determine building block approach con declineultimate trend sidere historical average real return asset class year rate reach ultimate trend rate incertain country historical return meaningful consideration give local market expectation longtermreturn onepercentagepoint change assume health care cost trend rate wouldhave follow effect onepercentage onepercentage dollar million point increase point decrease health care plan total interest service cost postretirement benefit obligation note consolidated financial statement thefollowing table set forth information relate thebenefit obligation fair value plan asset yearend thecompany define benefit retirement plan postretirement plan retirement plan benefit plan dollar million change benefit obligation project benefit obligationbeginning year service cost interest cost plan participant contribution amendment actuarial gainslosse divestiture acquisition curtailment settlement benefit pay plan effect exchange rate project benefit obligationend year change plan asset plan asset fair valuebeginne year actual return plan asset company contribution plan participant contribution divestiture acquisition curtailment settlement benefit pay plan asset effect exchange rate plan asset fair valueend year fund status end year unrecognize actuarial loss unrecognize prior service cost unrecognize net transition asset total recognize consolidated balance sheet amount recognize company balance sheet consist follow adoption sfas book accrual prepay benefit intangible asset accumulate comprehensive income total recognize consolidated balance sheet adoption sfa noncurrent asset current liability noncurrent liability total recognize consolidated balance sheet amount recognize accumulate comprehensive income consist net actuarial loss prior service costscredit unrecognized net transition asset total tax effect change accumulate comprehensive income adoption sfas tax effect accumulate benefit obligation end year include post employment benefit perthe adoption sfas johnson johnson annual reportstrategic asset allocation determine country base consider nonmature plan longterm strategic asset nature liability consider thedemographic allocation consistent type plan emphasis composition plan participant average age year ser place diversify equity abroadbasis combinedwith vice active versus retiree status thecompany plan currencymatche fix incomeasset thefollowing table display project future benefitpayment company retirement benefit plan dollar million project future benefit payment retirement plan benefit plansgross medicare rebate benefit plansnet thecompany require fund retirement plan appropriate meet longterm obligation plan require anticipate fund certain country united states funding meet minimum statutory fundingrequirement interna pension plan nota common practice funding provide tional plan fund accordance local regulation economic benefit consequently company additional discretionary contribution deemed pension plan notfunde thefollowing table display project future minimum contribution company international unfunded retirement plan amount include discretionary contribution company elect future dollar million project future contribution unfunde retirement plan unfunde international retirement plan thecompany retirement plan asset allocation december january target allocation follow percent target plan asset allocation retirement plan equity security debt security total plan asset international retirement plan equity security debt security real estate total plan asset thecompany benefit plan unfunded plan accumulate benefit obligation excess plan life insurance contract asset million million asset consist follow december january respectively thefair value johnson johnson common stock directly retirement plan dollar million hold planasset million total plan asset accumulate benefit obligation million total plan asset december project benefit obligation january respectively plan asset fair value note consolidated financial statement cash cash equivalent marketable security december january amortize unrealize estimate amortize unrealized estimate dollar million cost gainslosse fair value cost gainslosse fair value current investment cash government security obligation corporate debt security money market fund time deposit total cash cash equivalent current marketable security noncurrent investment marketable security financial instrument orequivalent credit rating average investment thecompany follow provision sfas require mature month company incur derivative instrument record balance sheet relate loss fair value december balance defer net gain saving plan derivative include accumulate comprehensive income million aftertax company expect substantially thecompany voluntary k saving plan design thisamount reclassify earning overthe enhance exist retirement program cover eligible monthsa result transactionsthat expect occur employee thecompany match percentage thatperiodthe maximum lengthof time overwhich company employee contribution consistent provision hedge transaction exposure month ulti plan heshe eligible mately realize earning differ foreign exchange rate salary plan onethird change realize gain loss ultimately determined company match waspaid company stock employee actual exchange rate maturity thederivative derivative stock ownership plan esop employee choseto gainslosse initially report component compre redirect investment establish esop hensive income reclassify earning period company loan million esop trust purchase forecast transaction affect earning share company stock open market exchange forthe year end december january company receive note balance wasrecorde january net impact hedge ineffectiveness transac reduction shareholder equity remainingshare hold tion qualify forhedge accounting discontinuance esop trust allocate participant account endof hedgesto company financial statement insignificant february march go forward com refer note disclosure movement accumu pany match cash follow individual employee late comprehensive income investment election total company contribution plan million million million concentration credit risk thecompany invest excess cash deposit major bank worldand high quality money market instrument thecompany policy make investment onlywith commercial institution johnson johnson annual report merger acquisition divestiture thefollowing table present preliminaryallocation certain business acquire billion cash purchase price relate consumer healthcare business billion liability assume acquisition pfizer inc date acquisition account purchase method accordingly dollar million result operation include financial state current asset ment respective date acquisition property plant equipment notedbelow goodwill december company complete acquisition consumer healthcare business pfizer inc intangible asset purchase price billion cash theoperate total asset acquire resultsof consumer healthcare business pfizer inc current liability bereporte company financial statement begin noncurrent liability result subsequent acquisition date total liability assume significant order obtain regulatory approval transaction net asset acquire company agree divest certain overlapping business company complete divestiture zantacproduct theacquisition consumer healthcare business pfizer december divestiture kaopectate inc result billion goodwill allocate unisom cortizone balmexand actproduct consumer segment january thepreliminary purchase price allocation theidentifiable thefollowing table provide pro forma result operation intangible asset include current period balance sheet thefiscal year end january fiscal year follows end december consumer healthcare busi dollar million ness pfizer inc acquire begin intangible asset determinable life period presentedthepro forma result include effect brand divestiture certain purchase accounting adjustment patent technology estimate change depreciation andamortization expense acquire tangible intangible asset customer relationship pro forma result include anticipate cost saving total amortizable intangible effect plan integration consumer health brand indefinite live care business pfizer inc accordingly amount total intangible asset necessarily indicative result acquisition occur date indicate occur future theweighte average life million total amortizable intangible approximately year pro forma result majority intangible asset valuation relate year end year end december january brand assessment brand indefinite life dollar million share datum determinable life base number net sale factorsinclude competitive environment market share net earning brand history product life cycle operating plan macro diluted net earning common share economic environment country brand sell indefinitelife brand account thecompany process finalize allocation thetotal value indefinitelife brand include listerine purchase price individual asset acquire liability nicorette neosporin sudafe benadryl visine assume thepreliminaryallocation purchase price benylin determinablelife brand include purell include current period balance sheet base well actife efferdentand regional country specific estimate management thecompletion purchase price brand determinablelife brand assetlive range allocation result adjustment carryingvalue yearsthe patent technology intangible consumer healthcare business pfizer inc record asset concentrate upper respiratory oral care medicate skin liability revision useful live intangible asset care tobacco dependence hair growth business determination residual allo assetlive range yearsthe estimate customer cat goodwill therelate depreciation andamortization relationship intangible assetuseful life range acquire asset subject revision base yearsreflect low historical project customer attri final allocation tion rate consumer healthcare business pfizer inc major retailer distributor customer theiprd charge relate acquisition consumer healthcare business pfizer inc million pretax basis million aftertax basis primarily associate right obtain pende switch zyrtecfrom prescription counter status note consolidated financial statement thevalue iprd calculate cash flow projec probability ofsuccess factor range tion discount therisk inherentin project aproba reflectinherent clinical regulatory risk discount rate bility success factor reflectinherent apply regulatory risk discount rate apply theiprd charge related acquisition ensure company process completingthe analysis medical inc million associate femoral integration plan pursuant company incur cost artery closure device thevalue iprd calculate primarily relate elimination certain duplicate sell cash flow projection discount therisk inherentin general administrative function company project aprobability success factor area global business service corporate staff reflectinherent clinical regulatory risk discount rate gotomarket support excess manufacturing capacity apply addition acquisition consumer healthcare certain business acquire million cash business pfizer inc acquisition include animas cor million liability assume acqui poration lead maker insulin infusion pump related sition account purchase method accord product hand innovation llc privately hold manufacturer ingly result operation include financial fracture fixation product theupper extremity future med statement respective date acquisition ical system sa privately hold company primarily devel theacquisition include transform pharmaceuti op manufacture market arthroscopic fluidmanagement cals inc company specialize discovery superior system vascular control systems inc privately hold com mulation novel crystalline form drugmolecule closure pany focus develop medical device treat fibroid medical corporation company expertise intellectual control bleed obstetric gynecologic application property biosurgical market peninsula pharmaceutical groupe vendme sa privately hold french marketer adult inc biopharmaceutical company focus develop baby skin care product colbar lifescience ltd privately commercialize antibiotic treat lifethreatening infection hold company specialize reconstructive medicine tissue right consumer andprofessionally dispense rem engineering ensure medical inc privately hold company brandtbrand oral care product whiten develop device postcatheterization closure toothpaste strip system mouth rinse femoral artery theexcess purchase price estimate fair value exclude acquisition consumer healthcare busi oftangible asset acquire amount million ness pfizer inc excess purchase price esti assign identifiable intangibleasset residual mate fair value tangible asset acquire amount record goodwill approximately million million assign identifiable intangibleasset identify value iprd primarily associate residual record goodwill approximately mil acquisition transform pharmaceuticals inc closure medical lion identify value iprd primarily associ corporation peninsula pharmaceuticals inc ate acquisition hand innovation llc future theiprd charge relate acquisition transform medical system sa vascular control systems inc colbar pharmaceuticals inc million associate lifescience ltd ensure medical inc research relate discovery application superior theiprd charge relate acquisition hand inno mulations thevalue iprd calculate cash vation llc million associate fracture flow projection discount therisk inherentin project repair technology thevalue iprd calculate thediscount rate apply cash flow projection discount therisk inherent theiprd charge relate acquisition closure project aprobability success factor range medical corporation million associate reflectinherent clinical regulatory risk omnexsurgical sealant vascular indication outside discount rate apply europe potential indication worldwide thevalue theiprd charge relate acquisition future med ofthe iprd calculate cash flow projection dis ical system sa million associate count therisk inherentin project aprobability nextra duo pump product technology valueof success factor vascular indication iprd calculate cash flow projection discount indication reflectinherent clinical regula therisk inherent project probability success factor tory risk thediscount rate apply vascular technology reflect inherent clinical indication andregulatory risk discount rate apply theiprd charge relate acquisition peninsula theiprd charge relate acquisition vascular pharmaceuticals inc million associate control systems inc million associate development doripenem phase iii clinical flostat system technology thevalue iprd calcu trialsthevalue iprd calculate cash flow late cash flow projection discount therisk inherent projection discount therisk inherentin project project aprobability success factor aprobability success factor reflect reflectinherent clinical regulatory risk discount inherent clinical regulatory risk discount rate rate apply appliedwas theiprd charge relate acquisition colbar theremaine million iprd associated lifescience ltd million associated acquisition international commercial rightsto certain patent evolence family product biodegradable dermal knowhow field sedation analgesia scott filler thevalue iprd calculate cash flow lab inc thevalue iprd calculate cash flow projection discount therisk inherentin project johnson johnson annual reportprojection discount therisk inherentin project warning instruction usethat accompany prod thediscount rate uct feasible predictthe ultimate outcomeof litiga certain business acquire million cash tion company believe liability result million liability assume acqui case willbe substantially cover exist sition account purchase method accord amount accrue company balance sheet ingly result operation include financial available thirdparty product liability insurance statement respective date acquisition multiple product johnson johnson subsidiarie sub addition term acquisition agree ject numerous product liability claim lawsuit include ment link spine group inc million cash ortho evra risperdal duragesicand charit pay owner link spine group inc base artificial disc asofdecember approxi thedate food drug administration fda mately claimant file lawsuit claim approve charitartificial disc total injury allegedly ortho evra claimants cash expenditure relate acquisition million respect risperdal respect duragesic theacquisition include merck interest respect charit claimant seek sub johnson johnsonmerck consumer pharmaceutical co stantial compensatory available punitive damage european nonprescription pharmaceutical joint venture includ numerous claim lawsuit unite statesrelating ingall infrastructure brand asset manage drug propulsid withdraw general sale com european joint venture egea biosciences inc exer panys janssen pharmaceutica inc subsidiary cise option acquire remain outstanding stock resolve currentlyenrolle settlement programswith own johnson johnson develop proprietary aggregate cap million paymentsby company technology platform call gene writer thatallow litigation concern propulsidi pende canada rapid highly accurate synthesis dna sequence gene class action person allege adverse reaction drug assembly construction large synthetic gene library recently certifiedthe johnson johnson subsidiaries responsible artemis medical inc privately hold company ultrasound marketing product vigorously defend xray visible biopsy site breast marker hybrid claim settlement deem appropriate marker commercial rightsto certain patent know field sedation analgesia scott lab inc affirmative stent patent litigation biapharm sas privately hold french producer marketer patent infringement action try delaware federal district skin care product center leadingbrand biafine court late cordis corporation cordis subsidiary asset micome privately own manufacturer spinal johnson johnson obtain verdict infringement patent implant primarily focus supply german market validity damage awards boston scientific corpora acquisition ambiskin care brand woman color tion boston scientific medtronic ave inc medtronic theexcess purchase price estimate fair value base number cordis vascular stent patent indecem tangible asset acquire amount million ber jury damage action boston scientific assign identifiable intangibleasset residual return verdictof million thejury medtronic record goodwill million relate fda action return verdictof million multiple posttrialpro approval charitartificial disc record addi ceeding appeal ensue respect verdict tional goodwill associated link spine group inc ultimate outcomestill subject uncertainty acquisition total addition intangible andgoodwill cordis arbitration claim medtronic accus million approximately million ing medtronic infringement sale stent product introduce identify value iprd associated scott lab medtronic subsequent product subject early acquisition thevalue iprd calculate cash action reference subsequent product find flow projection discount therisk inherentin project license medtronic pursuant license thediscount rate arbitration panel march arbitration proceed supplemental pro forma information ing determine royalty owe product persfas business combinationsandsfas january cordis file patent infringement action goodwill intangible assetsis provide boston scientific delaware federal district court impact aforementione acquisition mate accuse itsexpress taxusand libertestent infringe rialeffect company result operation cash flow palmaz patentthatexpire november theliberte financial position stent accuse infringe cordis gray patent divestiture mate expire june jury find express rialeffect company result operation cash flow taxusand libertestent infringe palmaz patent financial position libertestentalso infringe gray patent motion file boston scientific seek vacate verdictor obtain new trial deny june cordis expect boston scientific legal proceeding appeal court appeal federal circuit product liability thecompany involve numerous product liability case patent litigation united states concern adverse reaction johnson johnson subsidiaries drug medical device thedamage claim substan theproduct johnson johnson subsidiaries tial company confident adequacy thesubject patent lawsuit outcomes note consolidated financial statement couldpotentially adversely affect ability subsidiary damage willfulness injunctive relief appeal sell thoseproduct require payment past damage decide future royalty respect matter trialof boston scientifics case assert infringement johnson johnson subsidiary involve vigorously defend cypherstent boston scientifics grainger patent claim infringement dispute appro whichhadbeen schedule march hasbeen adjourned priate validity enforceability patent claim pende decision cordis motion summary judgment assert inthat case boston scientific seek injunction july jury federal district court delaware substantial damage find cordis cypherstent infringe boston scien boston scientific brought action belgium andthe tifics de patent cordis cypherand bx netherland kastenhofer patent enjoin manufac velocitystent infringe boston scientifics jang ture sale allegedly infringe catheter country patent thejury find patent valid boston recover damage thebelgian case pendingandno scientific seek substantial damage injunction hearing date set decision low court action june district court deny motion netherlands boston scientifics favor appeal cordis overturn jury verdict grant new trial cordis germany boston scientific action base move reconsideration decision reconsider de patent pende cordis cypherstent ation deny cordis appeal court appeal cordis successful action trial level thefederal circuit thedistrict court indicate consider boston scientific appeal thefollowing chart summarize patent lawsuit concern product johnson johnson subsidiariesthathave proceed trial jj plaintiff product company patent patent holder court trial date date file catheters cordis fitzmaurice medtronic ave ed tex stent delivery system drug elute cordis grainger boston scientific del stents corp drug elute cordis ding boston scientific germany stents corp twolayer cordis kasten boston scientific nd cal catheters hofer corp belgium forman stent cordis israel medinol multiple eu jurisdiction contact lense vision nicolson ciba vision md fla care trial date establish noninfringement invalidity unenforceability litigation filer ofabbreviate new drug patent event subsidiary company involve application anda successful action statutory month stay thefollowing chart indicate lawsuit pende generic expires rule district court obtain firm file abbreviate new drug application seek firm involve ability fda approval intro market generic form product sell subsidiary duce generic version product issue result company prior expiration applicable patent cover substantial market share revenue loss theproduct ing product theseanda typically include allegation company subsidiary note follow chart month stay expire expire respect anda challenge product brand patentnda generic trial date month product holder challenger court date file stay expire aciphex eisai teva sd ny mg delay janssen dr reddys sd ny release tablet mylan sd ny axert almirall teva sd ny mg orthomcneil neurologic concerta mcneilppc andrx del mg alza controlled release tablet johnson johnson annual reportbrand patentnda generic trial date month product holder challenger court date file stay expire ditropan xl orthomcneil mylan wv mg alza impax nd cal control release tablet ortho tri cyclenlo orthomcneil barr nj mg mg mg mg mg mg pepcidcomplete mcneilppc perrigo sd ny razadyne janssen teva del mylan del dr reddys del purepac del barr del par del alphapharm del razadyneer janssen barr nj risperdaltablet janssen mylan nj dr reddys nj mg tablet apotex nj risperdalmtab janssen dr reddys nj mg risperdaloral janssen apotex nj solution mgml topamax orthomcneil mylan nj mg tablet cobalt nj topamaxsprinkle orthomcneil cobalt nj mg capsule mylan nj trial date establish action mylan dr reddys laboratories action mylan involve orthomcneil risperdalrisperidone tablet mtab product ditropan xloxybutynin chloride court district court new jersey rule october thatthe september find ditropan xlpatentinvalid risperdalpatent valid enforceable infringe infringe mylan generic product thoseruling generic product issue enter injunction prohibit affirmed court appeal federal circuit mylan dr reddys marketing generic risperidone september mylan impax receive final fda product date early patent expiration decem approval launch product november ber mylan appeal rule week follow adverse rule ditropan action mylan respect patent xlanda litigation mylan september johnson topamax district court new jersey october johnson andalza receive seven antitrust class action grantedthe company subsidiary orthomcneil pharma complaint filedby purchaser product allege ceutical inc orthomcneilmotion preliminary johnson johnson alza violate antitrust law injunction bar launch mylan generic version state knowingly pursue baseless patent litigation oftopamax february district court grant delay entry market mylan impax orthomcneil motion summary judgment dismiss mylan claimthe patent obvious remain issue case company expect judgment case shortly enter orthomcneil mylan appeal note consolidated financial statement action impax involvingit anda reference december orthomcneil receive subpoena mcneilppcs product concerta mcneil alza corpo attorney office boston massachusetts seek docu ration subsidiary company dismiss preju ment relate marketing include alleged offlabel market dice claim infringement impax respect ing drugtopamaxtopiramate additional subpoena itsanda document serve june orthomcneil cooper respect matter johnson ate respond subpoenas october theus johnson subsidiary involve vigorously defend validity attorney office boston ask attorney orthomcneil enforceability assert infringement cooperate facilitate subpoena testimony itslicensor patent present orthomcneil employee federal grand jury boston cooperation secure testimony average wholesale price awp litigation additional witness grand jury request johnson johnson pharmaceutical sub andi provide sidiarie numerous pharmaceutical company january janssen receive subpoena defendant series lawsuit state federal court office inspector general office personnel involve allegation pricing market certain management seek document concern sale market pharmaceutical product amount fraudulent ingof payment physician connection actionable conduct thing company sale marketing clinical trial risperdal allegedly report inflated average wholesale price awp risperidone document subsequent thedrug issue case federal action request additional subpoena seek state action remove federal court consoli information marketing adverse reaction date pretrial purpose multidistrict litigation mdl risperdalwas receive attorney office federal district court boston massachusetts theplaintiffs eastern district pennsylvania november janssen thesecase includeclasse private person entity cooperate respond subpoena pay portion purchase drug issue base april company pharmaceutical awp state government entity thatmade medicaid pay company request submit information ment thedrug issue base awp mdl proceed senate finance committee use nominal pricing ing boston plaintiffs move class certification exception calculate good price medicaid rebate portion claim august trial judge program request send manufacturer certify massachusettsonly class private insurer provid drug reimburse medicaid program ing medigap insurance coverage private payer physi company pharmaceutical company respond cianadministered drug payment base awp request february request supplemental informa thejudge allow plaintiff filea new complaint seek tion receive senate finance committee proper party represent national class individu respond company pharmaceutical company al copayment physicianadministere drug august johnson johnson health care system cover medicare thecourt appeals decline allow inc hcs johnson johnson subsidiary receive subpoena appeal issue january court certify dallas texas attorney office seek document national class note trial massachu relate relationship group purchase settsonly class action concludedbefore massachusetts organization novation hcs johnson johnson district court december decision expect subsidiary thecompany subsidiary involve quarter thetrial judge schedule jurytrial respond subpoena begin april national class action behalf september ortho biotech inc ortho biotech individual pay copayment medicare b drug receive subpoena office inspector general trialin action broughtby attorney general state denver colorado field office seek document direct alabama make allegation relate awp isset november sale marketing procritepoetin alfa additional awp case broughtby attorney gen present dealing oncology inc eral expect beset trial healthcare service network oncologist ortho biotech respond subpoena july centocor corporation receive request thatit voluntarily provide document information thecriminal division attorney office districtof new jersey connection investigation centocor market ing practice subsequent request document receive theus attorney office thecompany centocor respond process respond request document information johnson johnson annual reportin march depuy orthopaedics inc depuy sale marketing sideeffect risperdal johnson johnson subsidiary receive subpoena interaction state official state attorney office districtof new jersey seek record formulary medicaidreimburse drug janssen concern contractual relationship depuy process respond subpoena orthopaedic surgeon surgeonsintraine involve november centocor receive subpoena hip knee replacement reconstructive surgery seek document connection investigation lead orthopaedic company know receive conduct office united states attorney similar subpoena depuy orthopaedic respond sub central district california centocor average poena followon subpoena document number sell price asp calculation remicadeunder employee depuyhave subpoena testify company contract purchase program centocor produce grand jury connection investigation material responsive subpoena andcooperating june senate committee finance theinvestigation request company produce information use february johnson johnson voluntarily dis byseveral pharmaceutical subsidiary educational close department justice doj secu grant similar request send major pharmaceutical rities exchange commission sec subsidiary outside company july committee specifically request united states believe improper payment information educational grant connection connection sale medical device small drug propulsid follow request receive market countrieswhich payment fall jurisdiction committee additional information january foreign corrupt practice actthe company provide july scios inc scios johnson johnson sub additional information doj sec cooperate sidiary receive subpoena attorney office agency review matter district massachusetts seek document relate september plaintiff employment discrimina sale marketing natrecor scio respond tion litigation initiate company federal subpoena early august scios advise district court new jersey move certify class investigation wouldbe handle attorney office african american hispanic salary employee com northern district california san francisco pany affiliate employ time september johnson johnson receive sub november present plaintiff seek monetary poena attorney office districtof massachusetts damage theperiod present include seek document relate sale marketing drug punitive damage equitable relief thecourt deny plain omnicare inc amanager pharmaceutical benefit tiff class certification motion december theplaintiff longterm care facilities thejohnson johnson subsidiary seek reconsideration decision thecompany dis involve respond subpoena employee put allegation lawsuit vigorously defend ofthe company pharmaceutical subsidiary subpoenaed testify grand jury connection thecompany whollyowne subsidiary thisinvestigation ethicon inc ethicon endosurgery inc hcs defendant january janssen receive civil investigative federal antitrustaction challenge suture endo demand texas attorney general seek broad cate mechanical contract group purchasing organization gorie document relate sale andmarkete hospital discount predicate hospital achiev risperdal janssen respond request october ing specify market share target category prod texas attorney general join qui tam action file uct trialin action conme v johnson johnson et al janssen texas state court allege label marketing sdny file november currently schedule risperdaland seek compensation allege adverse april conme allege damage billion reaction risperdal damage wouldbe treble antitrust law dam february johnson johnson receive subpoena age liability successfully establish trial late securities exchange commission sec request december early purport class action e document relate participation johnson file behalf purchaser endomechanical instru johnson subsidiaries united nations iraq oil food ment action file federal district court program thesubsidiarie cooperate sec pro thecentral district california ducing responsive document november amgen file suit hoffmann june depuy receive subpoena laroche inc district court thedistrict massa department justice antitrust division request document chusett seek declaration rocheproduct cera relate manufacture marketing sale orthopaedic roche indicate seek introduce device search warrant execute connection united states infringe number amgen patent concern investigation depuy respond request docu epo amgen license manufacture epo salein ment wake publicity subpoenadepuy serve civil antitrustclass action september janssen receive subpoena attorney general state california seekingdocument note consolidated financial statement united states companys ortho biotech inc subsidiary thedilute net earning share calculation include dilu nondialysis indication thesuit preliminarystage tive effect convertible debt decrease interest expense october wyeth inc initiate litigation delaware million million million tax year cordis corporation allege cordis breach respectively license supply agreement pursuant wyeth supply dilute net earning share exclude millionmillion cordis drug rapamycin connection million share underlie stock option cordis cyphersirolimuselutingstent cordis com respectively exercise price option wasgreater mence action delaware seek declaration average market value wouldresult anti breach occur dilutive effect dilute earning share thecompany involve number patent trademark lawsuit incidental business theulti capital treasury stock mate legal financial liability company respect claim lawsuit proceeding refer change treasury stock estimate certainty company opin amount millionsexcept treasury stock treasury stock ion base examination matter experience number share thousand share date discussion counsel theultimate outcomeof legal balance december proceeding net liability accrue company balance employee compensation stock option plans sheet expect material adverse effect conversion subordinate debenture companys financial position resolution repurchase common stock reporting period matter couldhave significant impact company result operation balance january cash flow period employee compensation stock option plan conversion subordinate debenture repurchase common stock earning share balance january thefollowing reconciliation basic net earning share employee compensation stock option plan dilute net earning share theyear end december conversion subordinate debenture january january repurchase common stock share million share datum balance december basic net earning share average share share common stock issue share outstandingbasic end potential share exercisable cash dividend pay share com stock option plan pare dividend share share repurchase share treasury stock method convertible debt share adjust average share outstandingdilute diluted net earning share johnson johnson annual report select quarterly financial datum unaudite select unaudited quarterly financial datum theyear summarize second fourth second fourth dollar million share datum quarter quarter quarter quarter quarter quarter quarter quarter segmentsale customer consumer pharmaceutical med device diagnostic total sale gross profit earning provision taxis income net earning basic net earning share dilute net earning share quarter include aftertax gain million guidant acquisition termination fee aftertax charge million inprocess research development iprd second quarter include aftertax charge million iprd quarter include aftertax charge million iprd fourth quarter include aftertax charge million iprd second quarter include aftertax charge millionfor iprd million tax benefit dueto reversal tax liability relate technical correction associate american jobs creation act fourth quarter include aftertax charge million iprd shift sale low tax jurisdiction expenditure high tax jurisdiction significant impact fiscal fourth quarter tax rate subsequent event fiscal quarter company complete acquisition conor medsystems inc acardiovascular device company billion cash fiscal quarter accordance regulatory approval acquisition consumer healthcare business pfizer inc company announce closing divestiture kaopectate unisom cortizone balmexand actproduct chattem inc million cash note consolidated financial statement management report internal control financial reporting section sarbanesoxley act information communication andmonitoringthecom management require assess effectiveness pany assessment include extensive documenting evaluating company internal control financial reportingas theendof testing design operating effectiveness internal fiscal year report base onthat assessment control financial report thecompany internal control financial reportingi effective december company complete theacqui management company responsible establish sition consumerhealthcare business pfizer inc ingand maintain adequate internal control financial close proximity completiondate ofthe acquisition report thecompany internal control financial report date ofmanagement assessment effectiveness ingisdesigne provide reasonable assurance reliabil company internal controlover financialreporte management ity company financial reporting preparation exclude consumerhealthcare business pfizer inc financial statement accordance generally accept assessment internal controlover financialreporte accountingprinciple thetotal asset consumer healthcare business internal control financial reporting matter pfizer inc primarily intangible asset goodwill design inherent limitation internal control represent company total asset fiscal financial reporting determine effective provide year end december reasonable assurance respect financial statement theoperate result consumer healthcare business preparation prevent detect misstatement pfizer inc acquire december report projection evaluation effectiveness future company financial statement begin period subject risk control inade result subsequent acquisition date significant quate change condition degree base company process assessment compliance policy procedure deteriorate describe abovemanagement conclude thecompany management assess effective december company internal control finan ness company internal control financial reporting cial report effective ofdecember make assessment company management assessment effectiveness criterion establishedby committee sponsor company internal control financial reporting decem organization treadway commission coso internal ber audit pricewaterhousecooper llp controlintegrate frameworkthesecriteria area independent register public accounting firm state ofcontrol environment risk assessment control activity report appear johnson johnson annual reportreport independent register public accounting firm shareholder board director audit conduct audit internal control financial johnson johnson report accordance standard public company accounting oversight board united states complete integrate audits johnson johnsons standard require plan perform audit obtain consolidated financial statement internal control reasonable assurance effective internal control financial reporting december accordance financial reporting maintain material respect standard public company accounting oversight audit internal control financial reporting include board united states opinion base audits obtain understand internal control financial present report evaluate management assessment testing evaluate design operating effectiveness internal consolidated financial statement control andperformingsuch procedure consider opinion accompany consolidated balance sheet necessary circumstance believe audit relate consolidatedstatement earning statement provide reasonable basis opinion equity statement cash flow present fairly mate company internal control financial reporting rialrespect financial position johnson johnson process design provide reasonable assurance subsidiary companyat december janu reliability financial reporting preparation financial ary result operation cash statement external purpose accordance generally flow year period end december accept accountingprinciplesa company internal control conformity accountingprinciple generally financial reporting include policy procedure accept united states america financial state pertain maintenance record reasonable ment responsibility company management detail accurately fairly reflect transaction disposi responsibility express opinion financial state tion assets company ii provide reasonable ment base audit conduct audits assurance transaction record necessary permit statement accordance standard public com preparation financial statement accordance generally pany accounting oversight board united states stan accept accountingprinciple receipt expendi dard require plan perform audit obtain ture company accordance reasonable assurance financial statement authorization management director company free material misstatement audit financial state iii provide reasonable assurance prevention ment include examine test basis evidence support timely detection unauthorized acquisition use disposition amount disclosure financial statement assess company asset couldhave material effect ing accounting principle significantestimate financial statement management evaluate overall financial state ofit inherent limitation internal control ment presentation believe audits provide reason financial reporting prevent detect misstatement able basis opinion projection evaluation effectiveness future peri discuss note theimplementation sfas od subject risk control becomeinadequate company change manner itaccount change condition degree compli pension benefit december ance policy procedure deteriorate describe management report internal control internal control financialreporte financial reporting management exclude con opinion management assessment include sumer healthcare business pfizerinc assessment accompany management report internal control internal control overfinancial reporting december financial reporting company maintain effective acquire company december internal control financial reporting december alsoexclude consumerhealthcare business base oninternal control integrate frameworkissue pfizerinc audit internal control overfinancial report committee sponsor organization treadway com ing total asset consumerhealthcare business pfizer mission coso fairly statedin material respect base inc represent related consolidated financial statement criterion furthermore opinion company amount ofdecember maintain material respect effective internal control financial reporting december base crite ria establish ininternal control integrate frameworkissue coso thecompany management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion new york new york managements assessment effectiveness com february panys internal control financial reporting base report independent register public accounting firm summary operation statistical data dollar million share figure sale customersus sale customersinternational total sale cost product sell sell marketing administrative expense researchexpense purchase inprocess research development interest income interest expense net portion capitalize income expense net earning provisionfor tax income provisionfor taxis income net earning percent sale customer dilute net earning share common stock percent return average shareholdersequity percent increaseoverpreviousyear sale customer dilute net earning share supplementary expense datum cost material service total employment cost depreciation amortization maintenance repair total tax expense supplementary balance sheet datum property plant equipment net addition property plant equipment total asset longterm debt operate cash flow common stock information dividend pay share shareholdersequity share market price share yearend close average share outstanding millionsbasic diluted employee thousand netof interest income include cost material service category include taxis income payroll property otherbusiness taxis summary operation statistical datashareholder return performance graph ear umulat e otal shareholderreturn johnson johnson n h n h n n ear gr jj h year ear umulat e otal shareholderreturn johnson johnson n h n h n n ear gr jj h shareholder return performance graph ra year ra shareholder return performance graph johnson johnson n h n h n n johnson johnson n h n h n n rreconciliation nongaap financial measure tableis provide reconcilecertain financial disclosure letter shareholder vs vs dollar million share datum change change net earningsa report inprocess research development iprd charge guidant acquisition agreement termination fee american job creation act ajca tax cost associate repatriation undistribute international earning tax gain associate technical correction net earningsa adjust diluted net earning sharea report inprocess research development charge guidant acquisition agreement termination fee american job creation act tax cost associate repatriation undistribute international earning tax gain associate technical correction dilute net earning sharea adjust thecompany believe investor gain additional perspective underlie business trend result provide measure net earning dilute net earning share exclude iprd charge guidant acquisition agreement termination fee tax cost associate fund repatriate tax gain associate technical correction ajca order evaluate ongoing business operation thesenongaap financial measure consider replacement read mostcomparable gaap financial measure reconciliation nongaap financial measuresprincipal office company require file dividend reinvestment plan johnson johnson plaza exhibit fiscal year plan allow partial new brunswick new jersey certifications section dividend reinvestment additional sarbanesoxley act sign chief monthly cash investment executive officer chief financial year johnson johnson common stock annual meeting officer addition company require brokerage commission service annual meeting shareholder submit certification sign chief charge stock purchase place april hyatt regency executive officer new york stock interested participate plan new brunswick albany street new exchange day follow need authorization form andor brunswick new jersey meeting annual meeting shareholder copy information computershare convene shareholder certification file previous year trust company na cordially invite attend formal notice post company corporate outside meet proxy statement proxy governance web site future certifica send shareholder hear impair tion post promptly file shareholder inquiry corporate governance common stock stockrelate matter copy companys annual report list new york stock exchange communicate directly computershare quarterly report form stock symbol jnj trust company na telecommunica q current report form k tion device tdd telephone number securities exchange commission shareholder relation contact service proxy statement annual report steven rosenberg outside available online wwwjnjcom share corporate secretary holder charge write request register shareholder wish receive secretary company principal investor relation contact electronic notice online access future address call louise mehrotra annual report proxy material instead outside vice president investor relation paper copy register online addition company wwweconsentcomjnj corporate governance web site web site wwwinvestorjnjcomgovernance transfer agent registrar wwwjnjcom shareholder company question stock holding principle corporate governance information certificate replacementtransfer dividend charter audit committee johnson johnson history address change direct compensation benefit committee wwwkilmerhousecom computershare trust company na nominate corporate governance royall st entire content committee policy business conduct canton johnson johnson employees code business conduct ethic member outside board director executive officer internet wwwcomputersharecomjnj copy document available shareholder charge write request secretary company paper publication postcon principal address sumer recycle fiber forest stewardship council certify chain custody manufacture green energy credit purchase electricity generate renewable energy source wind lowimpact hydro resources checkmarkandtree logo forest stewardship council follow trademark trade name johnson johnson affiliated company appear report day acuvue day acuvue define day acuvue moist warm active natural active photobarrier complex acuvue acuvue advance acuvue oasys advantage alza ambi ambi clear angioguard animas aveeno aveeno ultra calming babycenter bandaid benadryl biosense webster carefree carto cellsearch centocor charite cilag gmbh international clean clear compeed consta contour transtar cordis cortaid cypher select dacogen depuy depuy asr depuy microhip depuy mitek depuy orthopaedics depuy proxima discover doxil duragesic etrans echelon endopath endopath et endopath xcel eprexerypo ethicon ethicon endosurgery ethicon omnex evotech floxin genesearch gotab groupe vendome gynecare morcellex gynecare tvt secur harmonic ace harmonic wave helioplex invega ionsys janssencilag janssen pharmaceutical kk johnson johnson johnson johnson pediatric institute johnsons jurnista ky laboratories vendome lacreon le petit marseillais lifescan ligamax listerine lubriderm mammotone mcneil microtip milagro natrecor neosporin neutrogena neutrogena mineral sheers nicorette onetouch onetouch horizon onetouch ultra onetouch ultraeasy onetouch ultramini oros ortho ortho biotech orthoclinical diagnostic porocoat precise prezista primage procriteprex quick pack reach reach cleanpaste reach inbetween rembrandt remicade risperdal risperdal consta risperdal mtab sensual mist softlotion softwash soothe natural splenda stayfree sudafe surgiflo tibotec topamax touch massage tylenol ultram ultrapro velcade veridex viactiv virco visine vistakon vitros xianjanssen pharmaceutical yondelis zarnestra follow trademark company appear report aciphexpariet eisai co ltd acuson acunav siemens medical solution associado saude de familia china hospital management association chinese ministry health division child health conservation fund crescendo clearstream techonologies group plc dacogen mgi pharma elizabeth glaser pediatric aids foundation forest stewardship council glen c olsen hospital project mercy green power partnership healthy community healthy ecosystem world wildlife fund insead kentucky department public health levaquin daichi pharmaceutical co march dimes prematurity prevention medhanealem school project mercy nature conservancy neonatal resuscitation program regatta brivant ltd safe kid worldwide trust public land ucla management development institute ultram er biovail corporation environmental protection agency velcade millennium pharmaceuticals inc wilderness society world wildlife fund yondelis pharmamar corporate shareholder informationour credo believe responsibility doctor nurse patient mother father use product service meeting need high quality constantly strive reduce cost order maintain reasonable price customer order service promptly accurately supplier distributor opportunity fair profit responsible employee man woman work world consider individual respect dignity recognize merit sense security job compensation fair adequate working condition clean orderly safe mindful way help employee fulfill family responsibility employee feel free suggestion complaint equal opportunity employment development advancement qualified provide competent management action ethical responsible community live work world community good citizenssupport good work charity bear fair share taxis encourage civic improvement well health education maintain good order property privileged use protect environment natural resource final responsibility stockholder business sound profit experiment new idea research carry innovative program develop mistake pay new equipment purchase new facility provide new product launch reserve create provide adverse time operate accord principle stockholder realize fair return johnson johnson plaza new brunswick new jersey